mRNA genotyping by gold nanoprobes by Assunção, Maria Saraiva Mendes
 
 
 Maria Saraiva Mendes Assunção 
 
Licenciada em Biologia Celular e Molecular 
 
 
 
  
 
  
  
 
mRNA genotyping by gold nanoprobes 
 
  
 
Dissertação para obtenção do Grau de Mestre em 
Biotecnologia 
 
 
  
  
  
Orientador: Prof. Doutor Pedro Viana Baptista, Professor auxiliar, FCT/UNL 
Co-orientador: Doutor Gonçalo Doria, Investigador, FCT/UNL 
 
 
 
 
 
 
 
 
 
 
                                                 Júri:  
 
 
 Presidente:  Prof. Doutora Cecília Roque 
    Arguente:     Prof. Doutora Alexandra R. Fernandes 
    Vogal(ais):   Prof. Doutor Pedro Viana Baptista 
 
 
 
Mês e An 
 
Setembro 2011 
 
 
 
 
 
 
mRNA genotyping by gold nanoprobes 
 
 
 
 
 
 
Copyright Maria Saraiva Mendes Assunção, FCT/UNL, UNL 
 
 
 
 
 
 
 
 
 
A Faculdade de Ciências e Tecnologia e a Universidade Nova de Lisboa têm o direito, perpétuo e sem 
limites geográficos, de arquivar e publicar esta dissertação através de exemplares impressos 
reproduzidos em papel ou de forma digital, ou por qualquer outro meio conhecido ou que venha a ser 
inventado, e de a divulgar através de repositórios científicos e de admitir a sua cópia e distribuição com 
objectivos educacionais ou de investigação, não comerciais, desde que seja dado crédito ao autor e 
editor. 
 
 
 
I 
 
RESUMO  
A bionanotecnologia tem surgido como uma área com grande potencial para o diagnóstico 
molecular. Nomeadamente, a utilização de nanopartículas de ouro tem permitido o 
desenvolvimento de métodos de diagnóstico molecular mais sensíveis e com maior 
especificidade, a uma fracção do custo inerente aos testes convencionais.  
No presente trabalho investigou-se a capacidade das nanossondas de ouro detectarem alvos 
com diferenças de uma só base em moléculas de RNA recorrendo ao método colorimétrico de 
non-cross-linking. Como proof-of-concept foram desenhadas, sintetizadas e caracterizadas 
nanossondas de ouro para a detecção de três SNPs (c.2732C>T, c.3232A>G e o c.3238G>A) 
presentes no gene BRCA1, um gene associado ao cancro da mama hereditário. Com o intuito 
de obter materiais de referência susceptíveis de utilização para calibração do método, 
fragmentos genómicos amplificados a partir de amostras biológicas contendo as sequências de 
interesse foram clonados em vector apropriado para posterior transcrição in vitro/in vivo. 
Inicialmente, averiguou-se a capacidade das nanossondas detectarem oligonucletídeos  
sintéticos complementares, seguindo-se condições de maior complexidade através de spiking 
em RNA total de Saccharomyces cerevisiae. Por último, foram utilizados produtos de 
transcrição in vitro/in vivo. Foi possível detectar especificamente o alvo complementar em 
0.12pmol/μL numa proporção de 0.25% de alvo complementar/RNA total. Foi também possível 
discriminar ambos os alelos do SNP c.3232A>G directamente em RNA utilizando apenas 
0.08pmol/μL de transcrito sintetizado in vitro. No caso das amostras de transcritos in vivo, os 
resultados foram inconclusivos. 
 
 
Palavras chave: Bionanotecnologia; ensaio non-cross-linking; nanossondas de ouro; 
genotipagem em RNA; BRCA1. 
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ABSTRACT 
 
Bionanotechnology has emerged as a field with great potential for molecular diagnose. Namely, 
the use of gold nanoparticles has allowed the development of molecular diagnostic methods 
with greater sensitivity and specificity at a fraction of the cost inherent to conventional 
techniques.  
 
The present work assessed the ability of gold nanoprobes to detect targets with single base 
differences in RNA molecules following the colorimetric non-cross-linking method. As proof-of-
concept, gold nanoprobes were designed, synthesized and characterized to detect three 
different SNPs (c.2731C>T, c.3232A>G and c.3238G>A) in the BRCA1 gene, a gene 
associated with inherited breast cancer.  
Reference materials, susceptible to be used for the calibration of the method, were created by 
cloning genomic fragments amplified from biological samples containing the sequences of 
interest in an appropriate vector for subsequent in vitro/in vivo transcription. 
 
Initially, the ability of target recognition by the gold nanoprobes was assessed using synthetic 
oligonucleotides targets alone and spiked-in total RNA of Saccharomyces cerevisiae, and later 
using transcripts synthetized in vitro/in vivo. This study revealed the capacity of target detection 
up to 0.25% of complementary target/total RNA, for a final concentration of complementary 
target of 0.12pmol/μL. It was also possible to detect and discriminate both c.3232A>G SNP 
alleles using only 0.08pmol/μL of in vitro transcript. For the in vivo transcript samples the results 
were inconclusive. 
 
 
Keywords: Bionanotechnology; non-cross-linking assay; gold nanoprobes; RNA genotyping; 
BRCA1. 
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1. INTRODUCTION 
 
1.1 From genome to transcriptome 
 
The revealing of the human genome sequence in 2001 has given rise to a new post-genomic 
era with unprecedented benefits for the future of medicine and biotechnology
[1]
. Biomedical 
research has since focused on understanding the relationship between genetic factors, the 
environment and human traits. The big goal is to achieve a more efficient prediction, prevention, 
diagnosis and treatment of a disease, i.e. to reach a personalized medicine
[2,3,4,5]
. 
 
Genetic variability can be presented in many forms, including variable number of tandem 
repeats (VNTR), presence and absence of transposable elements, deletions, duplications, 
inversions and single nucleotide polymorphisms (SNPs)
[6]
. The latter is the most common one, 
being the cause of 90% of all variations in the human genome
[7]
. SNPs are single nucleotide 
variations within the genome that are present at least in 1% of a certain population
[8]
, and 
provide a powerful resource as disease biomarkers in genome wide association studies 
(GWAS)
[9]
. 
 
Genetic variation can influence gene expression, both qualitative and quantitative, thus making 
it essential to characterize the transcriptome towards understanding the development of 
diseases. The transcriptome is the complete set of transcripts (e.g. mRNA, rRNA, tRNA, miRNA 
and many others) and their expression level within a cell, in specific physiological conditions 
[10]
. 
SNP correlation in the transcriptome can be considered a quantitative trait. These correlation 
studies allow identification of genomic loci that regulate expression levels of mRNAs or proteins, 
known as expression Quantitative Trait Loci (eQTL)
[11]
. 
 
Few technologies have been developed for gene expression genotyping, such as enzymatic 
amplification and/or cleavage, hybridization and sequencing (Table 1.1). Most of these 
technologies need a first step of target DNA amplification provided by Polymerase Chain 
Reaction (PCR)
[12,13]
. In the case of RNA, it is required a prior conversion of RNA into its 
complementary DNA (cDNA) via a reverse transcriptase which is then amplified by common 
PCR, i.e. RT-PCR
[14,15]
. For mRNA quantification, a real time PCR can be performed via the 
generation of a fluorescent signal that can be correlated to the initial mRNA concentration in the 
sample, i.e. qRT-PCR
[15,16]
. Both PCR and real-time PCR techniques are usually expensive and 
time consuming, and are also error prone as most polymerases lack proof-reading activity. 
Nonetheless, PCR has been used to characterize single nucleotide variations, through allele 
specific PCR or amplification refractory mutation system (ARMS) approaches
[17]
. 
2 
 
Target amplification is also possible through isothermal amplification methods
[21]
, which enables 
DNA/RNA amplification without the thermocycling apparatus needed for PCR. Examples of 
these techniques are rolling circle amplification (RCA)
[22]
, loop mediated amplification (LAMP)
[23]
 
and signal mediated amplification of RNA technology (SMART)
[24]
. These methods achieve 
amplification at a constant temperature using DNA polymerases with strong displacement 
activity such as Pfu, Bst and Aac polymerases. RCA involves only one primer, which can be 
also the template. The hybridization of the primer to a circularized DNA (probe) enables 
numerous rounds of isothermal enzymatic synthesis by continuously progressing around the 
circular DNA
[22]
. The LAMP technique in contrast to RCA, requires a set of four (to six) specific 
designed primers. The amplification is also assured by a polymerase with displacement activity 
only in the presence of the complementary target. This method has been applied to the 
characterization of RNA molecules by adding a first step of reverse transcription. Through this 
approach, Curtis et al.
[26]
 managed to detect specific RNA sequences from HIV-1-infected 
individuals using blood directly from patients. More recently, using the same method, Li et al.
[27]
 
achieved real time detection and quantification of microRNAs in total RNA. Another isothermal 
amplification method is the SMART technique, which also enables detection of DNA or RNA 
targets by amplification of the signal of detection. It depends on two probes (extension and 
template), each having a complementary region to the target at adjacent positions to one 
another. When the probes encounter complementary target hybridization occurs and the DNA 
polymerase extends the extension probe by copying the template probe. This template probe 
possesses a T7 RNA polymerase promoter sequence. Only the double stranded sequence 
enables the activity of the T7 RNA polymerase, thus generating RNA copies. This technique 
has been used to detected gene expression by Wharam and co-workers
[24]
, where they 
accomplished the detection of the SMART amplified signal through an Enzyme Linked 
Oligosorbent Assay (ELOSA). 
 
Enzymatic cleavage is another genotyping approach based on the ability of certain enzymes, 
i.e. restriction enzymes, to cleave DNA by recognition of specific sequences. Restriction 
fragments length polymorphism (RFLP), can be used to characterize DNA/RNA once different 
sequences will have different patterns of cleavage by the specific restriction enzymes. The 
products can then be analyzed by gel electrophoresis
[48]
. This technique has the disadvantage 
of being dependent on the restriction enzymes available and thus to the restriction sequences. 
Another drawback is the impossibility to use RNA directly in RFLP analysis, since there are no 
known restriction enzymes for RNA cleavage
[49]
. Thus, genotyping RNA molecules by RFLP 
require a first step of RT-PCR to provide cDNA for enzyme recognition
[28]
.  
Another enzymatic method that allows the detection and quantification of mRNA, map mRNA 
termini and to determine the position of introns within the corresponding gene is the 
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Ribonuclease Protection assay. In this assay a high specific radiolabeled single stranded cRNA 
is synthesized and hybridized in excess to the target mRNA. Then a combination of RNaseA 
and RNaseT1 is used to digest the free mRNA and the digestion product is analyzed by 
polyacrylamide gel/microchip electrophoresis and autoradiography/phosphorImaging to reveal 
which mRNA was effectively protected from RNase digestion due to the formation of a duplex 
between the target mRNA and the cRNA probe
[31, 32, 33]
. 
 
Hybridization approaches are based on the capacity of hybridization between two 
complementary single stranded sequences and in the differences in stability of the formed 
double-strand. Examples of hybridization techniques for RNA analysis are Northern blot
[34,35]
, 
fluorescent in situ hybridization (FISH) assays
[36, 37,38]
 and Microarrays
[39, 40]
. Northern blot and 
FISH technologies are the only ones to directly detect RNA, by hybridization with labeled 
probes. FISH enables also the detection and localization of specific mRNA sequences in vivo. 
Microarray analysis is also based on hybridization specifically between the microarray probes 
and target sequences which are typically fluorescently labeled. The use of these platforms to 
quantify gene expression is achieved indirectly through hybridization between fluorescent 
labeled cDNA synthesized by RT-PCR and the microarray probes. However, the use of retro 
transcription for quantification of the RNA molecule does not allow the detection of subtle 
changes in gene expression. This is a big weakness once the levels of gene expression are 
very important to understand the biological process
[45]
. These techniques along with other 
hybridization techniques have some drawbacks typical of an hybridization method, such as the 
need for previous knowledge about the target DNA/RNA; high background noise due to cross 
hybridization; saturation of the signal; and, above all, limitations upon the hybridization 
efficiency that depends on the sequence
[40]
. 
 
Despite all the genotyping technologies available, sequencing is still the gold standard for 
genotyping, offering the highest degree of specificity and selectivity. During the last ten years a 
lot of improvements have been made in sequencing technologies. The main sequencing 
method is the Sanger method, based on electrophoresis of fluorescently labeled sequencing 
reaction products
[50]
. In the past 5 years plenty of new sequencing platforms have been 
developed, the so called ―massively parallel‖ sequencing or high-throughput second generation 
sequencing increasing the data output, e.g. pyrosequencing
[12]
. 
The Sanger method firstly designed for DNA sequencing has been adapted to analyze gene 
expression giving rise to many gene expression sequencing techniques. These include Serial 
Analysis of Gene Expression (SAGE)
[41]
, Cap Analysis of Gene Expression (CAGE)
[42]
 and Poly 
Multiplex Analysis of Gene Expression (PMAGE)
[43]
. These analyses of RNA consist in 
synthesizing cDNA from the purified transcripts, which is then cutted by an anchoring enzyme, 
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usually NIaIII. The linkers containing a restriction site sequence of a specific restriction enzyme 
that can cleave the cDNA in short tags are then joined to the cDNA. These tags are joined to 
form a chain, and undergo amplification by PCR, prior to sequencing. In the end it is possible to 
identity and characterize the absolute abundance of the analyzed transcripts. Moreover, the 
tags can be cloned, providing a library of that specific set of transcripts
[44]
. 
 
The most modern RNA sequencing technique is the so called RNA-seq, based on the new 
generation high-throughput sequencing platforms that were initially developed for the analysis of 
DNA
[46]
. Briefly, a population of RNA is converted to cDNA fragments with adapters attached to 
both ends. Each molecule with or without amplification is then submitted to high-throughput 
sequencing. This sequencing technique provides very important information about the 
transcriptome once it enables not only the detection but also the measurement of expression, 
by means of the absolute abundance of coding and non-coding transcripts. Other advantage of 
this high-throughput sequence method is the reduction of the required amount of RNA 
sample
[45]
. In fact, sequencing platforms are very important so as to identify previously 
uncharacterized genes and genes expression profiles of normal and pathological disease 
tissues
[44,46]
.  
 
Genotyping technologies are providing important information for the achievement of better 
diagnosis systems but current molecular diagnostic techniques are still out of reach for point-of-
care diagnostic due to mainly 4 reasons: they are time consuming, require expensive 
instruments and technical expertise, and also require big amounts of biological samples
[51,52]
. 
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Table 1.1 - Technologies for gene expression genotyping. The principle and their limit of 
detection are underlined.  
Principle Technology Limit of detection** Refs 
Enzymatic 
Amplification 
RT-PCR 
1 pg - 5 µg of total 
RNA 
[14, 15, 18,19 ] 
Real-time RT-PCR 
80 pg - 500 pg of total 
RNA or 6 to 60 copies 
of mRNA 
[15, 16, 20] 
Isothermal amplification  
(RCA, LAMP, SMART) 
10-20 copies of target 
RNA* 
[21, 22, 23, 24, 25, 26, 27] 
Enzymatic 
cleavage 
RFLP 0.5-1-μg of cDNA* 
[28, 29, 30] 
Ribonuclease Protection 
Assay 
5 femtograms of 
target RNA or 4,000 
to 5,000 copies of 
mRNA* 
[31, 32, 33] 
Hybridization 
Northern blot 
3 - 30 µg of total RNA 
or 0.01–0.025 fmol of 
target RNA or 10,000 
copies of mRNA 
[34, 35] 
FISH 1 RNA molecule/cell 
[36, 37,38] 
Microarray 
Down to 200ng of 
total RNA* 
[39, 40] 
Sequencing 
Based on Sanger method:                                                                                                 
SAGE, CAGE, PMAGE 
50 μg of total RNA* 
[41, 42, 43, 44] 
High-throughput 
sequencing:                                                    
RNA-seq 
500 pg of total RNA*
[45, 46, 47] 
* requires a step of retro-transcription and amplification to cDNA prior to detection 
** Limit of detection may vary according to the target mRNA expression in total RNA 
 
 
Moreover, in contrast to DNA, the RNA lacks for efficient genotyping technologies since almost 
all techniques indirectly detect RNA through cDNA. It is important to bear in mind that cDNA 
analysis can give an absolute abundance of the transcript but is subjected to the stochastic 
behavior of the transcriptase, which can ultimately corrupt the real concentration of transcripts in 
the cell, which can be crucial for clinical diagnosis. 
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1.2 Nanodiagnostics  
 
Nanodiagnostics can be defined as the use and control of nanomaterials combined with 
biomolecules for molecular diagnostics
[53]
. In general, the great advantage of working at the 
nanoscale is that biomolecules and nanostructures are at the same nanometer scale requiring 
less amount of sample while increasing sensitivity
[54,55]
. In particular, nanoparticles (NPs) have 
revealed to be very promising nanostructures for molecular diagnostics due to their unique 
physicochemical properties such as high surface to volume ratio; enhanced photoemission; high 
electrical and heat conductivity; and improved surface catalytic activity. These properties may 
vary depending on their size (e.g. 1-100nm) and composition which are usually inorganic 
materials
[56]
, such as noble metals (e.g Au, Ag, Pt)
[57]
, magnetic metals (e.g. Fe304, Co)
[58,59]
, 
semi conductors (e.g. CdSe, CdS)
[60,61]
 or a combinations of the previously mentioned
[62,63]
.  
Among these, noble metal NPs are the most promising for the development of diagnostic 
techniques due to their accessible synthesis and derivatization, and unique size and shape-
dependent optical properties
[64,65]
. 
For noble metal NPs smaller than the wavelength of the incident light, the interaction between 
the electromagnetic waves of light and the electrons across the NP’s surface induces 
oscillations of these electrons, giving rise to a phenomenon known as Surface Plasmon 
Resonance (SPR). This SPR is responsible for the enhancement of scattering and absorption of 
electromagnetic radiation across the noble metal NPs
[66]
, providing intense colors in the visible 
spectrum to the colloidal solutions. These optical properties are dependent on the composition, 
size, morphology, dielectric properties of the surrounding medium and inter particle 
distances
[67,68]
. Some of these properties have been explored in the development of new and 
faster molecular diagnostic techniques, with increased sensitivity and simplicity at lower costs. 
 
 
1.2.1 Gold Nanoparticles (AuNPs) 
 
Gold nanoparticles (AuNPs) are the most widely reported and promising noble metal NPs for 
biomedical applications, not only for their well-known syntheses methods, but also for their 
capacity of bioconjugation
[64]
. The most common method for AuNPs syntheses is the 
Turkevich’s method, which is based on the reduction of chlorauric acid with sodium citrate
[69,70]
. 
The citrate ions act both as reducing and capping agent, enabling a stable and modestly 
monodisperse colloid aqueous solution of AuNPs that can be easily derivatized with 
biomolecules usually through a thiol or amine moiety.  
Typically, a solution of colloidal gold exhibits a maximum SPR absorption band centered at 
520nm with a characteristic red color. Aggregation of the AuNPs leads to a decrease in the inter 
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particle distance and a concomitant lower resonance frequency, promoting a shift of the SPR 
absorption peak to longer wavelengths. As a consequence, the colloidal solution changes color 
from red to blue, a phenomenon that has been explored in the development of colorimetric 
molecular diagnostic methods
[71]
.  
AuNPs have been reported to be successfully bioconjugated with many different biofunctional 
groups such as antibodies
[72,73]
, carbohydrates
[74]
, peptides
[75]
 and oligonucleotides
[76,77,78]
 
towards a specific biomolecular recognition. The derivatization of AuNPs with thiol-modified 
oligonucleotides (i.e. Au-nanoprobes) has emerged as a promising next generation biomarker 
technology
[54, 65, 79]
.  
Taking advantage of the amazing AuNPs properties, several molecular detection methods with 
great potential for point-of-care diagnostic have been developed for the specific and sensitive 
detection of nucleic acids sequences. 
The capacity of single stranded nucleic acids (ssDNA) to non-specifically adsorb to the AuNP’s 
surface and increase the stabilization upon salt-induced aggregation has been explored by Li 
and co-workers
[80]
. In this colorimetric assay detection is based on non-functionalized AuNPs. 
The identification of specific sequences within a PCR amplicon is achieved by hybridization with 
ssDNA probes that would otherwise adsorb to the AuNPs surface and stabilize them. The 
hybridization of ssDNA probes with the amplicon inhibits their adsorptions to the AuNPs and, 
consequently, they aggregate upon an increasing ionic strength and the solution changes color 
from red to blue. If the amplicon has no complementarity to the ssDNA probes, they will remain 
adsorbed to the AuNPs providing an increased stability to the increasing ionic strength and, 
thus, the colloidal solution does not aggregate and remains red. This method has been 
successfully used for the characterization of single nucleotide variations in DNA. Nonetheless, 
this simple method has some drawbacks, mainly the limited control over the 
adsorption/desorption of the single stranded oligonucleotides which can give rise to false 
negatives/positive results
[80]
. 
 
 
1.2.2 Methods based in Au-nanoprobes 
 
Functionalized AuNPs have been used in a variety of formats towards the development of 
molecular diagnostics protocols.  
Electrochemical detection based on the hybridization between the oligonucleotide target and the 
Au-nanoprobe has proved to be very sensitive for DNA targets
[81]
. For example, DNA segments 
related to the BRCA1 breast-cancer gene have been detected with a detection limit of around 
1.2fmol
[82]
. Still, the electrochemical detection directly on RNA using Au-nanoprobes has not 
been reported so far. 
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The colorimetric detection of DNA based on Au-nanoprobes was firstly reported by Mirkin and 
co-workers in 1996
[76]
. This approach is known as cross-linking method because it uses two 
different Au-nanoprobes with complementary sequences to adjacent regions within the target. 
This way when hybridization of both Au-nanoprobes with the target occurs due to their 
complementarity, a cross-linked network between AuNPs is formed and the inter particle 
distance decreases, which leads to a colorimetric change from red to blue. The detection of a 
single-base mismatch in DNA targets can be successfully reached using this system with 
appropriate temperature control
[70]
.  
Mirkin et al. used Au-nanoprobes labeled with Raman-active dyes and oligonucleotides to 
accomplish multiplexed multicolor detection of DNA and RNA targets reaching a limit of 
detection of 20fM with a single base resolution
[83]
. Another example was provided by Glynou et 
al.
[84]
, where the detection of 500 copies of prostate-specific antigen through the hybridization 
with Au-nanoprobes in a chromatographic stripe (dipstick) can be achieved by naked eye. In 
this method, similarly to current pregnancy tests, biotinylated RT-PCR products are hybridized 
to a specific oligo(dA)-tailed probe and loaded on the chromatographic stripe. As the buffer 
migrates through the stripe, the biotinylated RT-PCR products are immobilized by streptavidin 
spotted in a specific location of the stripe. Finally, to detect the presence of the DNA target in 
the streptavidin spot, poly-dT Au-nanoprobes are used to hybridize to the poly-dA probe.  
A mRNA expression array was also recently demonstrated by Huber and co-workers
[85]
 by using 
a surface-immobilized probe to capture the complementary transcripts from total human RNA 
samples. After hybridization, poly- T(20) Au-nanoprobes hybridized to the -polyA tails of the 
captured targets. Through this method the authors were able to detect specific transcripts from 
0.5µg of human total RNA without enzymatic amplification.  
 
 
1.2.3 Non-cross-linking method (our method) 
 
A non-cross-linking method for detection of gene expression without the need for retro-
transcription was developed by Baptista and co-workers
[78]
. This approach relies on the 
differential stability of the Au-nanoprobes in the presence/absence of a complementary target 
upon increasing ionic strength of the solution. The presence of fully complementary target and 
its hybridization to the Au-nanoprobe prevents aggregation upon salt addition and the solution 
remains red. In contrast, the presence of a non-complementary target or a target harboring a 
single point mismatch cannot prevent the Au-nanoprobe aggregation upon increasing the ionic 
strength, and the solution changes color from red to blue.  
The mechanisms of stabilization by hybridization between target and Au-nanoprobe upon salt 
addition has been initially proposed to be due to an increase in the electrostatic repulsion 
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between Au-nanoprobes associated with the negatively charged backbone of the hybridized 
nucleic acid targets
[78,86,87,88]
. Recently, steric hindrance has also been thought to be associated 
to the stabilization in this non-cross-linking method, in which the hybridization to a 
complementary target provides a greater steric hindrance to the Au-nanoprobe and contributes 
to prevent inter-particle aggregation
[89]
. The method has been successfully applied to detected 
gene expression in 0.3 μg of total RNA without reverse transcription or PCR amplification
[78]
, 
and Mycobacterium Tuberculosis DNA in clinical samples after PCR amplification
[86]
 with a limit 
of detection of 0.75 μg of total DNA. The method is also able to discriminate single nucleotide 
polymorphisms in PCR products of relevant biological samples with a sensitivity of 75 
fmol/μL
[90,91]
. More recently, it has been reported the detection and quantification of the BCR-
ABL fusion transcript, which is responsible for chronic myeloid leukemia
[92]
. This detection was 
reached with discrimination of 50% of complementarity between the target and the Au-
nanoprobe, with a limit of detection of 10 ng/μl
[92]
. This method has also been described to have 
the ability to differentially detect two distinct target sequences in a multiplex colorimetric assay 
by using Au-nanoprobes combined with AuAg-alloy nanoprobes, taking advantage of different 
SPR absorbance peaks
[93]
. The colorimetric changes that occur in the non-cross-linking method 
can be assessed directly by the naked eye or quantified through UV-visible spectroscopy 
[78]
 or 
through the use of a light sensitive amorphous/nanocrystalline silicon pi’ii’’n photovoltaic sensor 
developed by the same authors
[94]
. The colorimetric changes can be quantified through a ratio 
between the SPR peak of the dispersed solution, around 525nm, and the aggregated SPR peak 
that shifts to longer wavelengths, usually 15 minutes after salt addition
[78,90]
. 
 
Once the non-cross linking method developed by Baptista and co-workers
[78
 have proved to 
have a single base resolution on DNA at room temperature and to have been successfully 
applied on the direct detection and quantification on mRNA, the work presented in this thesis 
aim to verify the possibility of the direct detection of single base differences directly on mRNA.  
 
 
1.3 Proof-of-concept: BRCA1 targets  
 
The breast cancer 1 (BRCA1) gene (MIM 113705), has been widely related to inherited breast 
and ovarian cancer
[95]
, with many different mutations related to cancer risk variations
[96]
. BRCA1 
gene is a tumor suppressor gene and the protein product has been associated to numerous 
nuclear functions such as transcription, recombination, DNA repair and checkpoint control
[97]
. 
This 100 kb gene is located on the long arm of chromosome 17 (17q21) and it harbors 24 exons 
encoding a 1863 amino acid protein
[95]
. Screening of the complete coding region of BRCA1 
gene is laborious, mainly because of the complex mutation spectrum and the large size of the 
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gene. Nonetheless, the strong linkage disequilibrium region within this gene enables haplotype 
based studies. The most frequent SNPs found in BRCA1 gene are used to characterize these 
haplotypes
[98]
. 
In this work, attention was focused on three of the most frequent SNPs present in BRCA1 gene, 
namely, c.2731C>T (dbSNP rs#: rs799917), c.3232A>G (dbSNP rs#: rs16941) and c.3238G>A 
(dbSNP rs#: rs4986852) – see also Table 1.2.  
 
Table 1.2- Allele frequencies of the most frequent BRCA1 SNPs 
SNP frequency according to HAPMAP-CEU 
 Wild-type Heterozygous Homozygous 
c.2731C>T 0.434 0.46 0.106 
c.3232A>G 0.442 0.451 0.106 
c.3238G>A 0.912 0.088 0 
 
All these variations are missense polymorphisms located within exon 11 of BRCA1. 
Nonetheless, their impact on risk of breast and ovarian cancer is not clear. Studies indicate that 
SNP c.3238G>A may play a role in disease predisposition
[99]
. The other two SNPs are generally 
found to be non-pathological
[100,101]
, although some associations with breast cancer have been 
found
[102]
. 
 
Genetic screening of high risk families for breast cancer is now available in most hospitals from 
developed countries. Namely, in Portugal this is carried out by the Department of Breast and 
Ovarian Cancer Risk Evaluation at Instituto Português de Oncologia (IPO). Currently, at IPO, a 
set of laborious and expensive pre-screening assays towards sample genotyping is required 
prior to sequencing of the samples of interest. Assessment of gene expression can also be an 
important tool since it is the deficient protein activity that is thought to be related to disease 
onset and development. Thus, the analysis of gene expression could help clarification on the 
involvement of the gene variants in the development of the disease. In fact, RNA studies in 
inherited breast cancer patients have previously revealed to be an important factor in the 
survival of chemotherapy
[103]
. Moreover, deficient RNA expression of BRCA1 gene has also 
been related to non-inherited breast cancer
[104]
. Therefore, the development of Au-nanoprobes 
for identification of the most frequent SNPs directly in mRNA of patients could help characterize 
the haplotypes of interest while reducing costs and screening time. By directly targeting mRNA, 
we might be able to retrieve valuable information regarding which allele is being expressed and, 
eventually, whether there is any deviation of the standard proportion of either allele expression 
level. Since the Au-nanoprobe system does not require prior retro-transcription and/or 
amplification, the eventual enzymatic performance bias would therefore be bypassed.   
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1.4 Objectives  
 
This work aimed at assessing the possibility of using DNA functionalized AuNPs (i.e. Au-
nanoprobes) to detect single nucleotide differences directly in RNA targets via the non-cross-
linking method. As proof-of-concept, the three of the most frequent SNPs found in BRCA1 gene 
were used as targets. 
To achieve this objective, several intermediate objectives were set forward to fulfill the ultimate 
goal: 
- amplicons from patient samples harboring the SNPs of interest were cloned into an 
expression vector so as to provide plenty of biological material for subsequent tests, to 
be used as templates for in vitro/in vivo transcription reactions and to transform suitable 
bacterial hosts to create an expression model 
- optimization of in vitro and in vivo expression of the SNP transcripts so as to produce 
the RNA targets required for method validation and calibration 
- synthesis and characterization of AuNPs suitable for functionalization with thiol-modified 
oligonucleotides 
- Au-nanoprobes for the detection of each SNP in RNA were designed and synthesized 
- Characterization of the Au-nanoprobes in terms of stability, capacity of hybridization and 
quantification of a synthetic ssDNA oligonucleotide target, alone and in spike-in 
mixtures of total RNA purified from suitable cells 
- Evaluation of the Au-nanoprobes detection capability in complex mixtures, mimicking 
real biological samples using in vitro transcription products alone and in spiked mixtures 
- Assessment of SNP discrimination within target RNA molecules.  
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2. MATERIALS AND METHODS 
 
2.1 Materials 
 
2.1.1 Equipment and specialized material 
- UV-Vis Spectrophotometer UV Mini-1240 (Shimadzu, Germany),  
- UV-Vis Spectrophotometer Nanodrop ND-1000 (Nanodrop Technologies, USA) 
- Microplate reader Infinite M200 with Absorbance module (Tecan, Switzerland) 
- Thermal Cycler DNA Engine (Bio-Rad, USA), Thermal Cycler Tgradient (Biometra, Germany) 
- Gel Doc XR+ Molecular Imager system (Bio-Rad, USA) 
- Ultrasonic bath Elmasonic S10H (Elma, Germany) 
- E-Gel® iBase™ Power System with E-Gel® Safe Imager and E-Gel® EX pre-cast gel, 2% 
(Invitrogen, USA) 
- pH meter Basic 20 with combined glass electrode 5209 (Crison, Spain) 
- Quartz absorption cells – 105.202-QS (Hellma, Germany) 
- 384 well small volume, LoBase Polystyrene microplates, black – Cat.No.788096 (Greiner Bio-
One)  
- NAP-5 columns (GE Healthcare, Sweden) 
- Costar® Spin-X® Centrifuge Tube Filters, 0.22 μm Pore CA Membrane Sterile (Corning, USA) 
- Spectra/Por 1 Dialysis Tubing, 10mm width, part no. 132645 (Spectrum Labs, USA) 
 
2.1.2 Chemical Reagents 
 
Table 2.1 - Chemical reagents 
Reagent 
CAS 
number 
Distributer 
Agarose 9012-36-6 Invitrogen 
Chloroform 67-66-3 
Merck 
Glacial acetic acid 64-19-7  
Magnesium chloride 7786-30-3 
Potassium chloride 744-40-7 
Sodium chloride 7647-14-5 
Sodium hydroxide 1310-73-2 
Sodium phosphate dibasic dihydrate 10028-24-7 
Sodium phosphate monobasic monohydrate 10049-21-5 
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Reagent (cont.) 
CAS 
number 
Distributer 
Ampicillin 69-53-4 
Sigma-Aldrich 
Boric acid 10043-35-3 
Glycerol 56-81-5 
Glucose 50-99-07  
Gold(III) chloride trihydrate 16961-25-4 
Manganese chloride 13446-34-9 
Methyl sulfoxide (DMSO) 67-68-5 
PIPES 5625-37-6 
Potassium hydroxide 1310-58-3 
Sodium citrate tribasic dihydrate 6132-04-3 
Sodium Dodecyl Sulfate (SDS) 151-21-3 
Ethylenediamine tetraacetic acid 60-00-4 
Fluka 
Dithiothreitol (DTT) solution, 1M 3483-12-3 
Phenol 108-95-2 
Tris(hydroxymethyl)aminomethane 77-86-1 
Diethyl Pyrocarbonate 4525-33-1 
Tryptone 91079-40-2 
Difco 
Bacteriological agar 9002-18-0 
Proteinase K 39450-01-6 Roche 
Yeast extract 8013-01-2 USB 
Gel red n.a Biotium 
Calcium chloride 10035-04-8 AppliChem 
Bacteriological agar 9002-18-0 Difco 
Peptone n.a Panreac 
Sodium acetate 6131-90-4  
Jose M. VAz 
Pereira, LDA 
 
2.1.3 Solutions 
 
10mM (Sodium) Phosphate buffer, (pH8) 
 
9.32 mM Na2HPO4  
0.68 mM NaH2PO4 
 
 
Synthesis Buffer I  2% (w/v) SDS  
10 mM Phosphate buffer, pH 8 
Sterilize by filtration and store at 4ºC.  
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Synthesis Buffer II 1.5 M NaCl  
0.01% (w/v) SDS  
10 mM Phosphate buffer, pH 8  
Sterilize by filtration and store at 4ºC 
 
AL I  
.  
50 mM Glucose  
25 mM Tris-HCl, pH 8 
10 mM EDTA, pH 8  
Sterilize by autoclaving and store at 4ºC. 
 
AL II  
 
200 mM NaOH 
1% (w/v) SDS 
Prepare fresh before use (room temperature). 
 
 
AL III  
 
3 M Sodium acetate (adjust pH to 4.8 with 
glacial acetic acid)  
Store at 4ºC. 
 
 
Luria-Bertani medium (LB medium) 1% (w/v) tryptone  
0.5% (w/v) yeast extract 
171 mM NaCl  
Adjust to pH 7 with NaOH. Sterilize by 
autoclaving and store at 4ºC.  
(For solid medium, add 1.4% (w/v) of Agar) 
 
 
Super Optimal Broth (SOB medium)  2% (w/v) tryptone  
0.5% (w/v) yeast extract 
10 mM NaCl  
2.5 mM KCl  
10 mM MgCl2 *  
10mM MgSO4*  
Adjust to pH 7 with NaOH. Sterilize by 
autoclaving and store at 4ºC.  
*Add sterile MgCl2 and MgSO4 just before use.  
 
 
Super Optimal broth with Catabolite 
repression (SOC medium) 
 
Same as SOB medium plus add 20 mM 
glucose (sterile) after autoclaving SOB 
medium and cooling down to 60ºC or less. 
 
 
Yeast Extract Peptone Dextrose medium 
(YPD medium)  
 
1% (w/v) yeast extract   
2% (w/v) Peptone  
2% (w/v) Glucose 
Sterilize by autoclaving and store at 4ºC. 
 
 
Terrific Broth medium (TB medium) 
 
10 mM PIPES  
15 mM CaCl2  
250 mM KCl  
55 mM MnCl2  
Adjust pH to 6.7 with KOH or HCl.  
Sterilize by filtration and store at 4ºC. 
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2.1.4 Biological Material 
 
2.1.4.1 Molecular Biology 
 
Enzymes 
DreamTaq DNA polymerase (Fermentas, Canada) 
T7 RNA polymerase (Fermentas, Canada) 
Restriction enzyme; XhoI and AluI (New England Biolabs, USA)  
DNAse I, RNase-free (Fermentas, Canada)\ 
Lyticase (Sigma-Aldrich,USA) 
Lysozyme (Sigma-Aldrich,USA) 
 
DNA size markers  
GeneRuler™ DNA Ladder Mix, ready-to-use (Fermentas, Canada)  
RiboRuler™ High Range RNA Ladder (Fermentas, Canada) 
 
Kits  
CloneJET™ PCR Cloning Kit (Fermentas, Canada) 
GeneJET™ RNA purification Kit (Fermentas, Canada) 
Quant-iT™ OliGreen® ssDNA Assay Kit (Invitrogen, USA) 
 
Microorganisms 
Escherichia coli DH5α  
Escherichia coli BL21 (DE3) pLysE (Bioline, USA) 
Saccharomyces cerevisiae CBS 8803 
 
2.1.4.2 Oligonucleotides  
 
All ssDNA oligonucleotides were acquired from STAB VIDA, Lda. 
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Table 2.2 - Primers 
Designation Sequence (5’ > 3’) 
Tm 
(ºC) 
Observation 
pJET1.2_Fw CGACTCACTATAGGGAGAGCGGC 60.4 
pJET1.2 primers 
pJET1.2_Rev AAGAACATCGATTTTCCATGGCAG 55.8 
pJET1_Fw GCCTGAACACCATATCCATCC 51.9 
For amplification of 
phage T7 promoter 
sequence  
BC1_2731_Fw 
TGGTACTGATTATGGCACTCAGGAA
AGTAT 
59.6 
Amplicon harboring 
SNP c.2731 (C/T) 
BC1_2731_Rev 
GTGACTTTTGGACTTTGTTTCTTTAA
GGACC 
59.5 
BC1_3232/38_Fw 
GGCAACGAAACTGGACTCATTACTC
CA 
59.8 
Amplicon harboring 
SNP c.3232(A/G) 
and SNP 
c.3238(G/A) 
BC1_3232/38_Rev 
GTTGCAAAACCCCTAATCTAAGCAT
AGCA 
60.2 
 
Table 2.3 - Synthetic ssDNA targets 
Designation Sequence (5’ > 3’) 
sBC1_2731C TTCAAAGCGCCAGTCATTTGCTCCGTTTTCAAATCCAGGAAATGCA 
sBC1_2731T TTCAAAGCGCCAGTCATTTGCTCTGTTTTCAAATCCAGGAAATGCA 
sBC1_3232_38AG 
ACATTAGAGAAAATGTTTTTAAAGAAGCCAGCTCAAGCAATATTAA
TGAAGTAGGTT 
sBC1_3232_38GA 
ACATTAGAGAAAATGTTTTTAAAGGAGCCAACTCAAGCAATATTAA
TGAAGTAGGTT 
 
Table 2.4 - Thiol-modified ssDNA probes 
Designation Sequence (5’ > 3’) Modification 
BC1_2731C TGCATTTCCTGGATTTGAAAACG 5’-thiol 
BC1_2731T TGCATTTCCTGGATTTGAAAACA 5’-thiol 
BC1_3232A TCTTTAAAAACATTTTCTCTAATGT 3’-thiol 
BC1_3232G CCTTTAAAAACATTTTCTCTAATGT 3’-thiol 
BC1_3238G AACCTACTTCATTAATATTGCTTGAGC 5’-thiol 
BC1_3238A AACCTACTTCATTAATATTGCTTGAGT 5’-thiol 
Note: Thiol-modified ssDNA were resuspended in 100 μL of 1 M DTT and incubated for 1 h at 
room temperature followed by the addition of 900 μL of sterile milli-Q water to achieve a final 
concentration of 0.1M DTT. 
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2.1.4.3 Human genomic DNA samples 
 
Human genomic DNA samples harboring SNPs in the BRCA1 gene were gently provided by 
Drª. Fátima Vaz from the Molecular Biology Department and Breast Cancer Risk Evaluation 
Clinic, Instituto Português de Oncologia de Lisboa, Francisco Gentil.  
 
Table 2.5 - Biological samples genotype 
SNP in BRCA1 
gene 
c.2731 (C/T) 
p.P871L 
rs799917 
c.3232(A/G) 
p.E1038G 
rs16941 
c.3238 (G/A) 
p.S1040N 
rs4986852 
Genotype CC TT AA GG GG GA 
 
 
2.2 Methods 
 
2.2.1 Target Sequence Preparation 
 
2.2.1.1 Preparation of competent E. coli cells (adapted from Inoue et al.
[105]
) 
 
1. E. coli DH5α cells were inoculated on a LB agar plate and incubated at 37ºC overnight.  
2. A large colony was inoculated in 125 mL SOB medium in a 500 mL flask and grown at 20ºC 
with vigorous shaking up to OD600nm = 0.5 (normally 24 - 36 hours).  
3. The flask was placed on ice for 10 min.  
4. Cells were pelleted by spinning at 1,663× g for 10 min at 4ºC.  
5. The cells were gently resuspended in 40 mL ice-cold TB and stored on ice for 10 min.  
6. Cells were pelleted by spinning at 1,663× g for 10 min at 4ºC.  
7. The cells were gently resuspended in 5 mL ice-cold TB and 350 μL DMSO (DMSO was 
stored at -20ºC o/n before use).  
8. Competent cells were aliquoted in 200 μL fractions and stored at -80ºC until use.  
 
2.2.1.2 PCR amplification 
 
Reaction Mixture 
Component per reaction (Vtotal=20μL) 
10X DreamTaq buffer inc. MgCl2  2 μL 
dNTP mix - 5 mM each 0.8 μL 
Forward primer - 10 μM 0.5 μL 
Reverse primer - 10 μM 0.5 μL 
Template DNA 100 ng 
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DreamTaq DNA polymerase - 5u/μL  0.1 μL 
Water, nuclease-free to 20 μL 
 
Reaction program 
A first target denaturation was performed at 94ºC for 2 min, followed by 25 cycles of PCR, each 
cycle consisting of 95ºC for 30 seconds, annealing at 60ºC for 30 seconds, extension at 72ºC 
for 45 seconds and with a final extension step at 72ºC for 7 min. 
 
These conditions were used for all PCR amplifications. Amplicons’ size and integrity were 
confirmed by electrophoresis (90 V, 1 hour) in 1% agarose gel with 1x TBE. The expected size 
of the amplicons can be found in Appendix A. 
 
2.2.1.3 Cloning 
 
2.2.1.3.1 Ligation 
 
1. The amplicons of interest were extracted using the E-Gel
®
 electrophoresis system with E-
Gel
®
 EX pre-cast 2% agarose gels, following the manufacturer's instructions. 
2.  The extracted amplicon (100 ng) was inserted into a linearized blunt-end pJET1.2 cloning 
vector using the GeneJET™ PCR Cloning Kit and following the manufacturer’s Sticky-End 
protocol. 
2.2.1.3.2 Transformation of E. coli DH5α 
 
1.  The ligation product (2 μL) was added to 20 μL of E. coli DH5α competent cells and let to 
rest on ice for 30 minutes. 150 ng of purified pUC18 plasmid was used as positive control and 
as negative control, the ligation product was replaced by sterile H2O. 
2. The cells were then submitted to a heat shock at 42ºC for 90 seconds and rapidly transferred 
to ice.  
3. After 2 minutes on ice, 80 μL of SOC medium was added and the cells were incubated for 1 
hour in a shaking water bath at 37ºC.  
4. After incubation, 100 μL of the transformed competent cells were cultured on LB agar plates 
with 100 μg/mL ampicillin and incubated o/n at 37ºC. 
5. Up to three transformed colonies were resuspended in 25 μL of sterile H2O. 
6. Two microliters of transformed cells were used to perform PCR using pJET1.2 Fw and a 
specific reverse primer to each inserted amplicon. The remaining cells were inoculated in 2 mL 
of LB medium with 100 μg/mL ampicillin and incubated o/n in a shaking water bath at 37ºC. 
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7. Stock solutions of the transformed cells were prepared by adding 300 μL of glycerol to 700 
μL of culture and stored at -80ºC. The remaining volume of culture was used to extract and 
purify the cloned plasmid, following step 2. onwards of the ―Plasmid extraction and purification‖ 
protocol. 
 
2.2.1.3.3 Transformation of E. coli BL21 (DE3) pLysE 
 
E. coli BL21 (DE3) pLysE competent cells (100 µl) were transformed with 10 ng of plasmid DNA 
(pBC1_2731C, pBC1_2731T, pBC1_3232_38AA and pBC1_3232_38GG) purified from the 
DH5α clones following manufacture’s transformation protocol. As positive control 200 pg of 
pUC19 plasmid provided by the manufactures were used. 
 
2.2.1.4 Plasmid extraction and purification  
 
1. An E. coli colony was inoculated in 2 mL of LB medium and 100 μg/mL ampicillin and 
incubated o/n in a shaking water bath at 37ºC.  
2. Cells were pelleted by spinning at 16,707× g for 2 min at 4ºC in 1.5 mL eppendorfs.  
3. The supernatant was discarded and the pellet was resuspended in 100 μL of ice-cold AL I 
solution.  
4. After 5 minutes on ice, 200 μL of AL II solution was added and mixed by inversion.  
5. After 5 minutes on ice, 150 μL of AL III solution was added and vigorously mixed by vortex.  
6. After 5 minutes on ice, the lysate was centrifuged at 21,460× g for 5 minutes at 0ºC.  
7. The supernatant was transferred to a sterile 1.5 mL eppendorf and 2 volumes of ice-cold 
absolute ethanol and 0.3 M of sodium acetate were added.  
8. The plasmid DNA was left to precipitate at -20ºC o/n (or at -80ºC for 2 hours).  
9. Afterwards, the precipitate was centrifuged at 21,460× g for 15 minutes at 0ºC and the 
supernatant was discarded. 
10. The pellet was washed with 500 μL of ice-cold 70% ethanol and centrifuged at 21,460× g for 
5 minutes at 0ºC.  
11. The supernatant was discarded and the pellet was dried using a speed-vac system and 
resuspended in 50 μL of sterile H2O.  
12. RNase A was added to a final concentration of 25 μg/ml and incubated for 1 hour at 37ºC.  
13. Two extractions with 1 volume of phenol were performed, followed by one extraction with 1 
volume of chloroform.  
14. To precipitate the plasmid DNA, the procedures from step 7 to 11 were repeated. 
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2.2.1.5 Purification of template for in vitro transcription 
 
The plasmids harboring the sequences of interest were used as template for PCR using the 
pJET1Fw primer and the reverse primer specific to each insert. The use of pJET1Fw primer 
allows the amplification of the phage T7 promoter sequence within the amplicon. The PCR 
amplification was carried out as described in 2.2.1.4 PCR amplification. The resulting 
amplicons were purified by phenol/chloroform extraction, followed by precipitation as described 
in 2.2.1.3 Plasmid extraction and purification, step 13 and 14. The pellet was then 
resuspended in 50μL of DEPC treated water. 
 
2.2.1.6 In vitro Transcription 
 
Reaction Mixture 
Component per reaction (Vtotal=50μL) 
15X Transcription buffer  10 μL 
NTP mix – 10mM each 10 μL 
Linear template DNA 1 μg 
T7 RNA polymerase 1.5 μL 
DEPC- treated water to 50 μL 
 
Reaction program 
 
The reaction mixtures were incubated at 37°C for 2 hours, followed by heat inactivation of the 
enzyme at 70ºC for 10 minutes. 
 
2.2.2.1.6.1. In vitro transcript purification  
 
A. Purification from agarose gel  
1. The in vitro transcript was purified by excision from 2% agarose gel after electrophoresis (40 
V, 2h30, 1x TAE).  
 
A.I - Squeeze and freeze 
 
1. The excised gel slice was frozen at -80°C during 20 minutes followed by centrifugation in a 
Spin-X tube according to the manufacturer’s instructions. The transcript was collected in 
microcentrifuge tube while the agarose is retained on the Spin-X membrane. 
2. Afterwards, the transcript was precipitated and washed as described in 2.2.1.3 plasmid 
extraction and purification, step 7 to 11.  
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The concentration and quality of the purified in vitro transcripts were determined by UV/Vis 
spectroscopy at 260nm and by the 260nm/230nm and 260nm/280nm ratios. The correct size 
and integrity of the transcript was verified by agarose gel (2%, 1x TBE) electrophoresis (90V, 
1h30). 
 
A.II - Electroelution in dialysis tubing 
 
Preparation of Dialysis Tubing 
1. Tubing were cut into pieces of 10 cm length and left to boil for 10 minutes in a large volume 
of 2% (w/v) sodium bicarbonate and 1mM EDTA (pH 8) treated with DEPC 0.1% (v/v). 
2. Dialysis Tubing were then thoroughly rinsed with water treated with DEPC and left to boiled 
10min in 1mM EDTA (pH 8) 
3. Tubing were allowed to cool and stored at 4ºC until further use. 
 
Electroelution  
1. One end of the bag was sealed with plastic clip, and the tubing was filled with 1x TAE buffer.  
2. The band on interest was excised from the gel (as mentioned in Purification of the gel step 1) 
and placed inside the tubing.  
3. The gel slice was allowed to sink to the bottom of the bag and the buffer was squeezed out 
leaving just enough to maintain the slice in contact with the buffer, and the bag was then sealed 
with another plastic clip. 
4. The bag was immersed in an electrophoresis tank, maintaining the gel slice in parallel with 
the electrodes. Electric current (30V) was applied for 40 minutes. 
5. Afterwards polarity was reversed for 1 minute to release any RNA that could adhere to the 
tubing. 
6. The bag was then opened and the TAE recovered, precipitated and washed as described in 
2.2.1.3 plasmid extraction and purification, step 7 to 11. 
 
B. Desalting NAP-5 column  
1. Purification of the in vitro transcript products through a desalting NAP-5 column, according to 
manufacturer’s instructions, using 500 µl of water treated with DEPC as eluent. 
 
C. Phenol/chloroform extraction  
1. Two extractions with 1 volume of phenol, followed by one extraction with 1 volume of 
chloroform were performed and left to precipitate with two volumes of absolute ethanol and 0.3 
M of sodium acetate at -20ºC o/n (or at -80ºC for 2 hours).  
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Note: For the NAP-5 desalting and phenol/chloroform extraction, elimination of the template was 
performed with DNAse I as described by the manufacture (2U of DNAse I per 50 μL of 
transcription reaction, at 37 ºC for 15 min). 
2.2.1.6.2 Target Quantification 
 
Quantification of synthetic ssDNA targets 
All synthetic ssDNA targets were quantified through UV-vis spectroscopy using the extinction 
coefficient at 260nm of each ssDNA oligonucleotides, calculated according to OligoCalc 
bioinformatic tool available on-line 
[106]
. 
 
Quantification of in vitro transcripts  
Quantification of the in vitro transcripts was performed by agarose gel (2%, 1x TBE) 
electrophoresis (90 V, 1h30) analysis, using the fluorescence intensity of a known DNA/RNA 
ladder as reference. For RNA quantification the comparison of intensity was made using the 
500 b fragment of the RNA ladder, RiboRuler™High Range, as reference. For the DNA 
template quantification, the 500pb fragment of the GeneRuler™ DNA Ladder Mix was used as 
fluorescent reference. The DNA template concentration within the purified transcripts was used 
to ensure that concentration of template does not exceeded the limits of detection reported 
(900ng)
 [90,91]
. 
 
2.2.1.7 Total RNA Extraction from S. cerevisiae 
 
An S. cerevisiae colony was inoculated in 400ml YPD medium and incubated o/n in a shaking 
water bath (150 rpm) at 25ºC. Yeast cells were harvested at the exponential phase of growth 
(OD600nm = 0.5 ~ 1). Total yeast RNA purification was performed using GeneJET™ RNA 
Purification as described in the manufacture’s protocol. Integrity of total RNA was verified by 
agarose gel (2%, 1x TBE) electrophoresis (90V, 1h30). The concentration and quality of the 
transcripts was determined by UV/Vis spectroscopy at 260nm and by 260nm/230nm and 
260nm/280nm ratios, respectively. 
 
2.2.1.8 IPTG induction of E. coli BL21 and total RNA extraction 
 
1. E.coli BL21 (DE3) pLysE clones harboring the plasmid pBC1_3232A_38A or pUC19 were 
inoculated in 100 mL of LB broth containing 50μg/ml of chloramphenicol and 100 μg/mL 
ampicillin and incubated o/n in a shaking water bath at 37ºC until stationary phase was reached. 
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2. Afterwards, a dilution with new LB broth (provided with the antibiotics mention in step 1) was 
performed to achieve 0.05-0.1 OD600. These cultures were incubated at 37°C until OD600=0.4 (~ 
3 hours). 
3. Each flask was split in two: one for induction with 1mM IPTG and the other with no addition of 
IPTG, for expression control, and cultures were let to shake for 2 hours at 37ºC. 
4. Total E.coli RNA extraction was performed by using GeneJET™ RNA Purification as 
described in the manufacture’s protocol. Integrity of total RNA was verified by agarose gel (2%, 
1x TBE) electrophoresis (90V, 1h30). The concentration and quality of the transcripts was 
determined by UV/Vis spectroscopy at 260nm and by the ratio 260nm/230nm and 
260nm/280nm. 
 
 
2.2.2 Nanoprobes Preparation 
 
2.2.2.1 AuNPs synthesis (adapted from Lee and Meisel
[107]
) 
 
All glass material used in the synthesis process was previously treated with aqua regia (1 vol 
HCL: 3 vol HNO3) and washed with ultrapure milli-Q H2O (18.2 MOhm.cm resistivity at 25 °C). 
 
1. In a 500 mL round bottom flask, 250 mL of 1 mM HAuCl4 were brought to a boil while 
vigorously stirring.  
2. While in reflux, 25 mL of 38.8 mM sodium citrate were quickly added and the mixture was 
kept refluxing for 15 minutes with continuous stirring.  
3. The colloidal solution was left to cool to room temperature while keeping the continuous 
stirring.  
4. The colloidal solution was then transferred to a 250 mL Erlenmeyer flask with a ground glass 
cap and stored in the dark at room temperature until further use.  
5. AuNPs concentration was determined by the Lambert–Beer law assuming a calculated molar 
absortivity for the plasmon resonance band maximum (526 nm) of 2.33×10
8
 M
−1
 cm
−1
. 
6. Morphological characterization of the AuNP was performed by Transmission Electron 
Microscopy (TEM). 
 
2.2.2.2 TEM analysis  
 
Samples of AuNPs were sent to Instituto de Ciência e Engenharia de Materiais e Superfícies 
(ICEMS/IST), Portugal, for TEM analysis. The samples were prepared by depositing 10 µL of 
the as-prepared colloidal solution in carbon copper grids, washing twice with 10 µL of Milli-Q 
water, and air drying the samples afterwards. TEM was performed with a HITACHI H-8100 
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microscope operated at 200 kV. Particle size and polydispersity were determined from the TEM 
pictures using the imaging software Carnoy 2.0, by analyzing at least 100 AuNPs. 
 
2.2.2.3 Nanoprobe synthesis - Ultrasound method (adapted from Hurst et al.
[108]
) 
 
1. Three extractions with two volumes of ethyl acetate to 500 μL of thiol-modified 
oligonucleotide were performed.  
2. The aqueous phase was further purified through a desalting NAP-5 column, according to 
manufacturer’s instructions, using 10 mM phosphate buffer (pH8) as eluent.  
3. The purified thiol-modified oligonucleotides were quantified by UV/Vis spectroscopy using 
the extinction coefficient at 260 nm provided by the manufacturer. Purified thiol-modified 
oligonucleotides were added to the colloidal solution of AuNPs in 1:200 (AuNP:oligos) ratio.  
4. Synthesis Buffer I was then added to achieve a final concentration of 10 mM phosphate 
buffer (pH8), 0.01% (w/v) SDS. The solution vial was then submersed in an ultrasound bath for 
10 seconds and let to rest at room temperature for 20 minutes.  
5. Afterwards, a certain volume of Synthesis Buffer II was added to sequentially increase ionic 
strength up the final concentration of 0.05, 0.1, 0.2 and 0.3 M NaCl, respectively. Aftereach 
buffer addition, the vial was submersed in an ultrasound bath for 10 seconds and let to rest at 
room temperature for 20 minutes before the next increment.  
6. After an o/n period at room temperature, the functionalized AuNPs were distributed in 1.5 mL 
eppendorfs and centrifuged at 21,460× g for 20 minutes. 
7. The supernatant was discarded and the resulting oily pellet was washed twice with 1 mL of 
10 mM phosphate buffer (pH8) and once with 1 mL of PBS solution  
8. The supernatant was then finally redispersed in 500 μL/eppendorf of the same PBS solution. 
The resulting solutions of each eppendorf were then gathered in a polypropylene 25 mL vial 
with a conical skirted base and stored in the dark at 4ºC until further use.  
9. The final concentration of functionalized AuNPs (i.e. Au-nanoprobes) was determined by the 
Lambert–Beer law assuming a molar absorptivity for the plasmon resonance band maximum 
(526 nm) of 2.33×10
8
 M
−1
 cm
−1
. 
10. Au-nanoprobes aliquots (13 nM) were prepared from stock solution using PBS as eluent 
and stored in the dark at 4ºC until further use. 
 
2.2.2.4 Au-nanoprobes stability assays  
 
1. Solutions were prepared according to the following table 2.6. 
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Table 2.6 - Stability assays 
Component Stock Concentration Final concentration* 
Au-nanoprobe 13 nM 2.5 nM 
MgCl2 0.3 M 0, 20, 30, 40, 50, 60 and 70 mM 
or   
NaCl 4 M 0, 0.1, 0.5, 1, 1.5, 2 and 2.5 M 
*10 mM phosphate buffer was added to fulfill a final volume of 30 µL 
 
2. The solutions were heated for 10 minutes at 95ºC and let to cool for 30 minutes at room 
temperature. 
3. Salt was added to the solutions and UV–visible spectrum were registered 15 minutes after 
salt addition.  
 
2.2.2.5 Non-cross-linking hybridization assay  
 
1. Assay solutions were prepared by mixing the Au-nanoprobe solution (final concentration of 
2.5 nM) to the appropriate target (final concentration varied from 0.03 pmol/μL to 1 pmol/μL), 
and using 10 mM phosphate buffer to fulfill the final volume (60 μL for spectrophotometer 
measurements or 30 μL for microplate measurements). As targets: the complementary target is 
fully complementary to the probe (detecting the allele of interest), the mismatch target has only 
one base of difference (i.e it mimics the non-complementary allele for the same locus). As 
negative control a non-complementary target was added to solution, i.e a target from other 
locus than the one tested in the assay. A blank solution was prepared replacing DNA/RNA 
targets with 10mM phosphate buffer.  
2. The solutions were heated for 10 min at 95ºC and then allowed to cool down for 30 minutes 
at room temperature. 
3. MgCl2 was added to the final concentration determined by the Au-nanoprobe stability assays. 
UV-visible spectrum were registered 15 minutes after salt addition. 
 
Spike-in assay 
Assays were performed with 2.5 nM of Au-nanoprobes in a final volume of 30 μL. Fixed 
concentrations of the ssDNA oligonucleotide target (complementary or non-complementary 
target, as described in 2.2.2.5 Non-cross-linking hybridization assay step 1, were added to a 
final concentration of 120 fmol/μL (1.6 ng/μL). Total RNA of S.cerevisiae was added to a final 
concentration of 1.6, 160, 228.6, 400, 640 ng/μL, in order to have decreasing % of ssDNA 
synthetic oligonucleotide target within the assays. To fulfill the final volume, 10mM phosphate 
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buffer (pH8) was added. A blank assay was performed by adding only S.cerevisiae’s total RNA. 
As negative control an assay was performed with a non-complementary target. 
 
2.2.2.6 Determination of Au-nanoprobes’ density by fluorescent assays (adapted from 
Sato et al.
 [109]
)  
 
1. To release the thiol-oligonucleotides from the AuNPs surface, DTT was added (final 
concentration 100 mM) to 2.5 nM Au-nanoprobes in a total volume of 100 μL 1x TE.  
2. Standard solutions were prepared by sequentially diluting thiol-modified oligonucleotides 
harboring the same sequence as the probes (concentration range: 7.81 to 250 nM), submitting 
these solutions to the same conditions as Au-nanoprobes’ samples, as described in step 1. 
3. Following 48 h at room temperature, both standard and sample solutions were centrifuged at 
21,460× g for 20 minutes and 50 μL supernatant were used to quantify the ssDNA in solution by 
using the Quant-iT™ OliGreen® ssDNA Assay kit according to the manufacturer instructions. 
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3. RESULTS AND DISCUSSION 
 
3.1. Biological Sample preparation  
 
Human genomic DNA samples harboring SNPs in the BRCA1 gene were gently provided by 
Drª. Fátima Vaz from Instituto Português de Oncologia de Lisboa, Francisco Gentil (Table 2.5 
2.1.4.6 Human genomic DNA samples). Based on these variants a set of synthetic 
oligonucleotides were designed to harbor the sequence variants of interest and used to test the 
capacity of Au-nanoprobes hybridization to the complementary targets (sBC1_2731C, 
sBC1_2731T, sBC1_3232_38AG and sBC1_3232_38GA). Simultaneously to achieve the in 
vitro/in vivo transcripts needed for the proof-of-concept, human genomic DNA samples 
harboring the SNP of interest were cloned into a pJET1.2 vector and subsequently transformed 
in E. coli DH5α, to guarantee a more stable insert and higher plasmid yield, and in E. coli 
BL21(DE3) pLysE, for in vivo transcription. The pJET1.2 vector harbors a T7 promoter 
sequence allowing in vitro or in vivo transcription of the insert sequence (Appendix B - Figure 
A.1). After screening of the correct orientation of the insert (by PCR screening) four different 
clones were sequenced (Appendix C): two clones harboring a 381 bp sequence with the 
c.2731C or c.2731T allele (pBC1_2731C and pBC1_2731T, respectively); and two clones 
harboring a 394 bp sequence with the c.3232A and c.3238A or c.3232G and c.3238G alleles 
(pBC1_3232_38AA and pBC1_3232_38GG, respectively).  
 
3.1.2 In vitro transcription 
An in vitro transcription was carried out using amplicons as template, which were obtained by 
PCR amplification of the cloned fragments, as described by the manufactures. The transcripts’ 
integrity was confirmed by agarose gel electrophoresis for which the plasmids pBC1_2731C/T 
provide a transcript with 431 bases (b) and the plasmids pBC1_3232_38AA/GG a transcript with 
444 b. Figure 3.1 shows the products of transcription, obtained from the pBC1_2731C, where 
the transcript (lower molecular weight) can be observed along with the DNA template and 
another product, a hybrid DNA/RNA. 
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Figure 3.1- In vitro transcription. Agarose gel (2%, 1x TBE, 0.5x Gelred TM) electrophoresis (80 V, 
1h30). 1) Template BC1_2731C for transcription (473 bp); 2) in vitro transcription (resulting transcript of 
431b) using BC1_2731C as template; 3) in vitro transcription using BC1_2731C as template, after 
incubation with DNAseI; L) RiboRuler
TM
High Range RNA Ladder. 
 
The in vitro transcript cannot be directly used in detection assays because it induces 
aggregation of Au-nanoprobes prior to the hybridization step (3.3.2 in vitro RNA transcript). 
This issue has been previously described and the aggregation was suggested to be induced by 
the components within the transcription buffer
[110]
. Additionally, the presence of the template 
may also interfere with transcript quantification and probe stabilization. For these reasons the in 
vitro transcripts needed to be purified prior to their use in the non-cross-linking assay. This task 
revealed to be the most difficult one in the development of this work. 
The extraction and purification of the transcript from agarose gel electrophoresis is a simply way 
to ensure only the presence of the RNA molecules of interest and, therefore, have a greater 
control over the assays. However to avoid contaminations or transcript damage, only a part of 
the agarose gels containing samples for slicing reference were stained with the fluorescent dye 
and submitted to UV light. The remaining gel was free from dye and UV exposure and the 
samples were sliced using the stained part of the gel as reference. Afterwards, purification of 
the transcript products within the slice of gel was carried out by two different methods: 
  i) squeeze and freeze method using a Spin-X tube. In this method the gel slice is frozen and 
then eluted through a column by centrifugation, retaining the agarose and the transcript and 
buffer are collected. This method allowed to isolate RNA (Appendix D, Figure A.2), but with a 
very low yield not sufficient to be used in the non-cross-linking assays.  
 ii) membrane dialysis. The possibility that a significant amount of transcript could remain in 
the agarose fraction or in the column’s membrane, leaded to try a purification using membrane 
dialysis. This method revealed to have even less yield and, therefore, there was a need to 
change the purification strategy. 
1       2      3      L 
1500 b 
 
1000 b 
 
500 b 
200 b 
31 
 
Since the transcription buffer strongly induces nanoprobe aggregation, thus being the main 
impeditive cause for carrying out the assays, the next step was to purify the transcription 
product. Two different approaches were made in parallel. 
 iii) NAP-5 column, a desalting column. A simple elution of the in vitro transcription product 
through a NAP-5 column had been effective for other transcription products purification used for 
detection by the non-cross-linking method 
[110]
. Unfortunately, in this case, the purified product 
induced stabilization of the Au-nanoprobes in the negative control. These results will be 
discussed later (see 3.3 in vitro RNA transcript detection). 
iv) phenol/chloroform extraction. T7 RNase manufacturers’ suggest a phenol/chloroform 
extraction for the purification of the transcript and removal of the polymerase enzyme. This 
method revealed not to interfere with the capability of detection of the Au-nanoprobe system 
(see 3.3 in vitro RNA transcript detection). 
 
These two last purification strategies do not manage to eliminate the DNA template from the 
purified solution. For this reason, an incubation with DNAse I was also performed. As a result, 
the DNA template and DNA/RNA hybrids were digested, but hydrolysis of RNA alone was also 
observed as it can be observed in Figure 3.1. This may be due to contamination of RNases in 
the DNase I. In fact residual RNase activity in DNase preparations have been already reported 
[111]
. Considering this, the colorimetric assays with in vitro transcripts were performed without 
digesting the samples with DNase I and a parallel assay with the template alone was also 
performed to rule out the possible interference of the DNA template (see 3.3 In vitro 
transcript).  
 
3.2 Synthesis and Characterization of Au-nanoprobes 
 
Synthesis of AuNPs 
 
Gold nanoparticles were synthesized following the citrate reduction method
[107]
. The resulting 
colloid suspension of AuNPs was then characterized by UV/Vis spectroscopy and transmission 
electron microscopy (TEM) (Figure 3.2A).  
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Figure 3.2 - AuNPs characterization. (A) TEM image of AuNPs. (B) Size histogram corresponding 
to the measurements of 120 AuNPs. AuNPs diameter (nm)= 14.2±1.5 (Average±STD) 
 
AuNPs showed an average diameter of circa 14 nm, as determined by the measuring of 120 
NPs from 5 TEM micrographs (Figure 3.2B), in agreement with previous reports following the 
same method
[90,91,92]
.  
 
Probe Design 
 
To study the single base mismatch resolution of the non-cross-linking method in RNA 
transcripts, three different SNPs located in the BRCA1 gene coding region were used as proof-
of-concept. For each SNP two probes were designed in order to detect each allele. The probes 
were derived from the complete coding sequence of BRCA1 (GenBank accession no. U14680). 
In order to hybridize to the RNA, the thiol-modified oligonucleotides were designed to be the 
antisense sequence, so as to be complementary to the RNA target. 
The probes harbored between 23 to 27 nucleotide sequences and were designed such as the 
polymorphism is located in the position further from the AuNP, hence the opposite end from the 
thiol moiety, in order to maximize availability to hybridization as previously described by Doria et 
al. 
[88]
. For this reason all probes were designed in order to have the SNP site recognition in the 
opposite end of the thiol moiety that was located at the 5’end for all probes, except for two 
probes: BC1_3232A and BC1_3232G, that have the thiol moiety at the 3´end. These two last 
probes were designed with a 3’- thiol moiety so as to recognize the SNP c.3232A>G and avoid 
the superposition of the probe sequence with the nearby SNP c.3238G>A. This way, an 
independent discrimination between the two different SNPs using four different probes (i.e. 
BC13232A/G and BC1_3238G/A) may be attained (Figure 3.3).  
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Figure 3.3 - Complementarity between probes and targets. The BC1_3232A probe, with the 
variant nucleotide in the 5´end of the modified oligonucleotide, and BC1_3238G probe, with the variant 
nucleotide in the 3’ end of the modified oligonucleotide, both hybridize to the synthetic oligonucleotide 
sBC1_3232_38AG. 
The AuNPs functionalization was performed according to the ultrasound method described by 
Hurst et al.
[108]
 and using a ratio of 200 oligonucleotides per AuNP. This method is preferred 
over the so called classic method described by Storfhoff et al.
[70] 
since it has been reported to 
allow better reproducibility between batches and to be less time consuming
[89]
. Thus, a total of 
six Au-nanoprobes sequences were designed to detect each possible allele of the three SNP of 
interest, in order to characterize homo- and heterozygotes individuals (see Table 3.1). 
 
Table 3.1 - Au-nanoprobes and their fully complementary targets. Synthetic ssDNA targets 
and plasmids harboring the template for in vitro/in vivo transcription.  
Au-nanoprobe  
Synthetic ssDNA 
oligonucleotide 
Plasmids/ Transcription 
products 
BC1_2731C sBC1_2731C pBC1_2731C 
BC1_2731T sBC1_2731T pBC1_2731T 
BC1_3232A sBC1_3232_38AG pBC1_3232_38AA 
BC1_3232G sBC1_3232_38GA pBC1_3232_38GG 
BC1_3238G sBC1_3232_38AG pBC1_3232_38GG 
BC1_3238A sBC1_3232_38GA pBC1_3232_38AA 
 
Characterization of Au-nanoprobes 
 
The characterization of Au-nanoprobes’ stability upon increasing ionic strength is essential for 
an efficient target detection by the non-cross-linking colorimetric assay, i.e. the determination of 
the minimum ionic strength necessary to induce aggregation or the Critical Coagulation 
Concentration (CCC). 
To determine the CCC values of the synthesized Au-nanoprobes, a set of titration assays with 
the Au-nanoprobes and increasing concentrations of NaCl or MgCl2 were performed and the 
UV-visible absorption spectrum were registered in order to detect the colorimetric changes 
associated with AuNPs’ coagulation/aggregation.  
The differences in stabilization between the AuNPs and Au-nanoprobe for 0.1M NaCl can be 
observed in Figure 3.4. The added salt revealed to be sufficient to induce a complete 
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aggregation of the AuNP alone which can be observed by the shift of the SPR band from 
525nm to 700nm, but did not induce aggregation of the Au-nanoprobes, which remained with 
the SPR maximum peak unaltered at 525nm. 
 
Figure 3.4 – AuNPs vs Au-nanoprobes stability. UV-visible absorption spectrum of the AuNPs 
and Au-nanoprobes in the presence of NaCl. AuNPs alone (AuNP) and AuNP or Au-nanoprobe in the 
presence of 0.1 M NaCl (AuNP with 0.1M NaCl and Au-nanoprobe with 0.1 M NaCl, respectively). 
 
 
Only two nanoprobes (i.e. BC1_2731C and BC1_2731T) aggregated with the addition of 2.5 M 
NaCl. On the other hand, all Au-nanoprobes aggregated in the presence of ≥40 mM MgCl2. 
When compared to the AuNP alone, the increased stability of the Au-nanoprobes (e.g. ≥2.5 M 
for Au-nanoprobes vs. <0.1 M NaCl for AuNPs) indicates an efficient functionalization of AuNP 
with the thiol-modified ssDNA, which is known to increase the AuNP stability to salt induced 
aggregation
[112]
. The MgCl2 electrolyte was chosen to induce aggregation in the non-cross-
linking assays, since it was the only one capable of inducing aggregation in all Au-nanoprobes. 
Additionally, the use of NaCl involved the addition of large volumes to the solution, which 
restricted the capacity of adding other analytes to the assay, such as the target. Aggregation of 
Au-nanoprobes as function of salt concentration can be easily followed by the red-shift of the 
SPR peak – Figure 3.5.  
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Figure 3.5– Au-nanoprobe stability to increasing salt concentration. UV-visible absorbance 
spectrum of the BC1_2731T Au-nanoprobe to increasing MgCl2concentrations (0 to 60 mM). Inset: Abs 
ratio vs. MgCl2 concentration. Error bars represent standard deviation of three independent assays. 
 
 
Differences in stability and capacity of hybridization have been related to Au-nanoprobe 
density
[112, 113]
. Thus it was also important to quantify the modified oligonucleotides immobilized 
to the AuNPs’ surface. The quantification of Au-nanoprobe density for each Au-nanoprobe was 
achieved by fluorescence measurements after the release of the thiol-modified oligonucleotide 
with DTT.  
The CCC values determined for MgCl2 for each probe are shown in Table 3.2 as well as the 
maximum SPR absorbance peak and the quantification of the thiol-modified oligonucleotides at 
the AuNP’s surface. 
 
Table 3.2- Characterization of Au-nanoprobes. Au-nanoprobes’ maximum SPR peaks upon 
salt aggregation, CCC and oligonucleotides density at AuNPs’ surface for all Au-nanoprobes. 
Probe 
SPR peak upon aggregation 
(nm) 
CCC for MgCl2 
(mM) 
Au-nanoprobe density 
(oligo/NP) 
BC1_2731C 562 40 64 
BC1_2731T 562 50 111 
BC1_3232A 605 40 56 
BC1_3232G 605 40 81 
BC1_3238A 564 40 170 
BC1_3238G 564 70 34 
 
The CCC values are similar for all Au-nanoprobes (40 mM MgCl2), except for the BC1_3238G 
probe (70 mM MgCl2). This difference could be related to differences in Au-nanoprobe density, 
since higher Au-nanoprobe densities have been reported to confer higher stability to salt 
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induced aggregation
[112]
. However, this seems not to be the case since the BC1_3238G probe is 
the least functionalized but shows the highest CCC value. Moreover, the CCC Au-nanoprobe 
stability for all the other Au-nanoprobes seems also not to be related to their surface 
functionalization, i.e. the CCC value remains constant despite the significant differences in their 
functionalization. Many other factors have been reported to be associated to differences in 
stability, such as sequence and length of the probe, secondary structures, etc
[112]
. These could 
compensate for the differences in surface functionalization and explain the similar CCC values 
observed for the majority of the Au-nanoprobes. 
Besides CCC determination for each probe, Au-nanoprobe characterization allowed to 
determine the maximum SPR shift of each probe essential to data treatment. The Au-
nanoprobe SPR absorption band peaks upon salt addition (SPR of the aggregated form) varied 
from 562nm to 605nm and were specific to each probe, i.e. they are maintained between 
different batches of the same Au-nanoprobe, indicating a possible major influence of the probe 
sequence.  
In order to quantify and better assess AuNP/Au-nanoprobe maintenance of dispersion after salt 
addition, a percentile ratio (%Dispersion) was calculated, see Equation 1. The absorbance ratio 
(Abs ratio) is obtained by the ratio between the absorbance of the maximum wavelengths 
characteristic to the dispersed and aggregated form of each Au-nanoprobe.  
 
                 
                                         
                                               
      , 
Hence for each non-cross linking assay the %Dispersion was calculated relatively to a blank 
assay - Au-nanoprobe alone with salt, which gives the Abs ratio to the maximum aggregated 
form, and an assay performed without adding any salt, which gives the Abs ratio of the 
dispersed form. At the CCC, values of %Dispersion near zero are associated with Au-
nanoprobes that have aggregated, for which the solution color changes from red to blue. On the 
other hand, the higher the %Dispersion, the more stable is the Au-nanoprobes system, where 
100% of %Dispersion is related to the Au-nanoprobes without salt addition.  
To define a threshold between a negative and a positive assay, in this work a negative result 
was considered to be the %Dispersion that falls in between the signal of the negative control (a 
non-complementary target) plus three times their standard deviation (Adapted from Zhang et 
al.)
[114]
. It is well mention that some absorbance shifts can be caused by other factors that are 
not due to SPR shifts, like precipitation and variations in optical path length (e.g. in microplate 
reader measurements), these shifts were corrected by performing the normalization at 400nm, 
once the influenced by SPR changes due to aggregation in this wavelength is minimized.   
Equation 1. 
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Target recognition - Synthetic oligonucleotide  
 
The capacity of hybridization of the Au-nanoprobes to a complementary target was first tested 
using synthetic oligonucleotides as targets. The %Dispersion of each Au-nanoprobes in the 
presence of their complementary, mismatched and a non-complementary targets is presented 
in Table 3.3 and as an example the values obtained for BC1_2731C are graphically 
demonstrated in Figure 3.6. 
 
Table 3.3- Non-cross-linking assay using synthetic ssDNA targets  
Au-nanoprobe 
( 2.5nM) 
%Dispersion (average of three assays ± STD) 
Complementary target 
(1pmol/μL) 
Mismatch target 
(1pmol/μL) 
Non-complementary target 
(1pmol/μL) 
BC1_2731C 66 ± 7 66 ± 3 1.7 ± 1.3 
BC1_2731T 81 ± 8 77 ± 5 0.2 ± 5 
BC1_3232A 49 ± 4 52.1 ± 3.5 3 ± 2 
BC1_3232G 98 ± 3 90 ± 6 3 ± 2.5 
BC1_3238A 68 ± 1.4 69 ± 0.5 2 ± 0.3 
BC1_3238G 34 ± 4 16.6 ± 1.8 3 ± 2.6 
 
All Au-nanoprobes presented a much greater %Dispersion when in the presence of a 
complementary/mismatch target, while the presence of a non-complementary target did not 
prevent the Au-nanoprobe aggregation. These results further confirm the efficient 
functionalization of the AuNP with the thiol-modified oligonucleotides and their capacity to 
effectively hybridize to the corresponding complementary targets. Furthermore, the differences 
of %Dispersion observed between Au-nanoprobes designed for the same locus may have a 
contribution of different levels of functionalization, where a better %Dispersion is achieved for 
the more functionalized Au-nanoprobes in the presence of their complementary targets (see 
also Table 3.2) 
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Figure 3.6 - %Dispersion of Au-nanoprobes with ssDNA upon salt addition. As an example, 
the %Dispersion for theBC1_2731C probe in the presence of the complementary t (sBC1_2731), 
mismatch (sBC1_2731T) or non-complementary (sBC1_3232AG) target is presented. The targets final 
concentration was 1 pmol/μL and spectrum data was registered 15 minutes after the addition of 40 mM 
MgCl2. Error bars represent standard deviation of three independent assays. 
 
 
Discrimination between complementary and mismatched targets was not possible for all Au-
nanoprobes with exception to BC1_3238G probe, for which the discrimination between 
complementary and mismatch was possible. This incapacity of mismatch discrimination when 
using ssDNA oligonucleotides has been previously reported, but was overcome when using 
asymmetric PCR products as targets, suggesting a dependence of the single base resolution on 
length and complexity of the target
[89]
. Considering this, the detection of a single mismatch 
within in vitro/in vivo transcripts may still be possible, despite the results observed for the 
ssDNA oligonucleotides.  
 
Limit of detection 
 
The limit of detection of the Au-nanoprobe is also an important parameter to take into account 
when developing a genotyping method, as well as the determination of the capacity of target 
quantification. Quantification of different alleles’ expression is an important tool in gene 
expression analysis. Therefore, the non-cross-linking assays were performed in the presence of 
increasing target concentration up to 0.2 pmol/μL (as an example, see Figure 3.7). 
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Figure 3.7 - Non-cross-linking target quantification. As an example, the %Dispersion of the 
BC1_2731C probe in the presence of increasing concentrations of complementary (sBC1_2731C) and 
non-complementary (sBC1_3232_38AG) ssDNA targets is presented. Spectrum data was registered 15 
minutes after the addition of 40 mM MgCl2. Error bars represent standard deviation of three independent 
assays. 
 
 
Since the complementary and mismatch synthetic oligonucleotide targets presented the same 
efficiency of stabilization, these assays were only pursued with complementary and non-
complementary targets. Mostly all Au-nanoprobes presented a limit of detection of 0.03 pmol/μl 
and a linear trend line within the range of 0.03 to 0.12 pmol/μl of complementary target, as one 
can see in the example of Figure 3.7. Above the 0.12 pmol/μL, the %Dispersion remained 
unchanged, most likely due to hybridization saturation. For the non-complementary target, the 
%Dispersion remained negligible for all the tested target concentrations. These results indicate 
that the Au-nanoprobes are capable of detecting a complementary target and can be used to 
quantify target concentration until saturation is reached.  
 
Spike-in assays 
 
In order to understand the sensitivity of the Au-nanoprobes in a more complex mixture and try to 
mimic an assay in total RNA from clinical samples, where mRNA is usually only 5% of the total 
RNA, a spike-in assay was performed using increasing concentrations of an unrelated total 
RNA from eukaryotic cells (i.e. S. cerevisiae) while maintaining unaltered the concentration of 
the synthetic oligonucleotide target. The chosen target concentration was the one at which 
%Dispersion saturation is achieved, i.e. 0.12 pmol/μL. Since the Au-nanoprobes have been 
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designed to detect BRCA1 mRNA, which is a low expression gene, the concentration of total 
RNA chosen were the ones that would make the 0.12 pmol/μL of target present in 1%, 0.7 %, 
0.4% and 0.25% of total RNA. To control the influence of the total RNA alone, a blank assay 
was performed using only total RNA for each concentration. The blank assay was subtracted to 
the complementary and non-complementary assay (Figure 3.8). 
The %Dispersion provided by the complementary target remained unaltered for up to 0.7% of 
target in total RNA, slightly decreasing for lower target/total RNA percentages (i.e. 0.4 and 
0.25%). The total RNA alone revealed to increase the Au-nanoprobes’ %Dispersion upon salt 
addition with increasing concentration of total RNA. Most likely this is due to the presence of a 
huge amount of single stranded nucleic acids which can adsorb non-specifically to the AuNP 
surface, thus providing great stabilization against salt induced aggregation 
[112]
. For this reason 
the %Dispersion for 0.4 and 0.25% of complementary target decreases and this may also be 
the reason to the increase in %Dispersion observed for the non-complementary target (behavior 
more pronounced in the BC1_2731T probe (Figure 3.8 B). The decrease of % Dispersion 
observed for the complementary oligonucleotide may also be due to the increase of entropy of 
the system which can hamper the hybridization of complementary targets to the Au-
nanoprobes. Nonetheless, the discrimination between complementary and non-complementary 
target was possible for all the tested target/total RNA ratios. 
 
 
Figure 3.8 - RNA spike-in assay. %Dispersion of Au-nanoprobe (BC1_2731C probe (A) and  
BC1_2731T probe (B)  with decrease % of complementary (red bars) and non-complementary (blue bars) 
targets in total RNA, 15 minutes after addition of 40 mM MgCl2. The target final concentration was 0.12 
pmol/μL spiked-in with increasing concentrations of S. cerevisiae total RNA. Error bars represent standard 
deviation of three independent assays. 
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3.3 in vitro RNA transcript detection 
 
Once the probes have been thoroughly characterized and calibrated, their capacity for in vitro 
transcription detection was tested.  
As mentioned before, the direct use of in vitro transcription cannot be applied in the non-cross-
linking detection assays since the product of transcription induces aggregation of Au-
nanoprobes (Figure 3.9). The SPR absorbance peak of the assays with complementary and 
non-complementary targets is centered at 730nm. This is an enormous shift of the SPR 
absorbance peak when compared to the blank assay, suggesting that something in the 
transcription product promotes a further Au-nanoprobe aggregation to the level of the 
unmodified AuNP. One hypothesis could be the reduction of the thiol-modified oligonucleotides 
by the presence of DTT which could remove the oligonucleotides from the NPs surface, leading 
to a bigger SPR shift
[112]
. 
 
 
Figure 3.9- Non-cross-linking assay with unpurified in vitro transcripts. UV-visible 
absorbance spectrum of BC1_2731C probe without salt (Au-nanoprobe) and salt addition (Blank), and in 
the presence of unpurified complementary (complementary target) and non-complementary (non-
complementary target) in vitro transcripts. The final concentration of target was 0.1 pmol/μL and spectrum 
data was registered 15 minutes after the addition of 40 mM MgCl2 (except for ―Au-nanoprobe‖ where 
MgCl2 was substituted by 10mM phosphate buffer (pH8)). 
 
To try to circumvent the problem mentioned before and following the purification problems 
mentioned in 3.1. Biological Sample preparation, two purification techniques were 
approached in parallel. The NAP-5 approach for purification of the in vitro transcript did not 
prove to be effective. In this case, both complementary and non-complementary targets 
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revealed to stabilize the Au-nanoprobes upon salt addition (Figure 3.10). Once the NAP-5 
column does not exclude enzymes, one possibility of this strong non-specific stabilization can 
be due to the presence of T7 RNA polymerase which can adsorb to the AuNPs’ surface, 
similarly to what occurs to other proteins 
[115,116,117]
. On the other hand, when purifying the in 
vitro transcript through the phenol/chloroform extraction (which enables the exclusion of the T7 
RNA polymerase) the discrimination between complementary and non-complementary mRNA 
targets has been finally achieved (Figure 3.10). Hence, the phenol/chloroform extraction was 
the method used for the subsequent in vitro transcripts purification. 
 
  
Figure 3.10 - Effect of transcript purification on the non-cross-linking method. Colorimetric 
assays with BC1_2731C probe in the presence of a complementary (BC1_2731C) and non-
complementary (BC1_3232A) in vitro transcripts purified by two different techniques: NAP-5 and Phenol/ 
Chloroform extraction. The final concentration of target was 0.1 pmol/μL and spectrum data was registered 
15 minutes after the addition of 40 mM MgCl2. 
 
 
The mRNA transcripts were quantified through agarose gel electrophoresis since the 
phenol/chloroform purification does not rule out the presence of the template DNA and 
DNA/RNA hybrids, which can interfere with transcript quantification through UV/visible 
spectroscopy. Therefore, the amount of RNA was estimated by comparison between the 
fragment intensity of the sample and the nearest fragment of the RNA ladder (i.e. 500 b). The 
RNA from the DNA/RNA hybrid and the DNA template present in the transcription product may 
also hybridize to the Au-nanoprobes and, thus, stabilize them against salt induced aggregation, 
interfering with the RNA assays. However, the DNA/RNA hybrid could not be quantified due to 
the lack of a corresponding ladder or a reference sample with a known concentration that would 
enable quantification of such molecules. Nevertheless, the presence of such RNA does not 
present an issue, since disregarding the contribution of such RNA is only going to affect the 
assessment of the assay sensitivity to mRNA and not its capability for SNP detection in RNA. 
On the other hand, the presence of the dsDNA template is believed not to interfere with 
hybridization, since the template concentration is below the limit of detection described for the 
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non-cross-linking assay with DNA samples (i.e. 900 ng of total DNA)
[90,91]
. Even though, a 
parallel assay was performed in order to check if the template could provide stabilization to the 
Au-nanoprobes against salt induced aggregation. The concentration of template used was 
600ng, which exceeded the concentration of DNA template present in the RNA detection 
assays and still no stabilization of the Au-nanoprobes to salt induced aggregation was 
observed. Therefore, we can exclude the contribution of the template to the stabilization of the 
Au-nanoprobes and, hence, only the remaining RNA can eventually provide such stabilization. 
Finally, having defined the purification method for the in vitro transcripts, the non-cross-linking 
assay was tested for the single base resolution of the non-cross-linking in RNA molecules, 
using in vitro RNA transcripts. For this purpose, 0.03, 0.06 and 0.08 pmol/μL of transcript were 
used, as shown in Figure 3.11.  
 
 
Figure 3.11 - SNP detection assay with in vitro transcripts. BC1_3232A probe (A) and 
BC1_3232G probe (B) in the presence of 0,03, 0.06 and 0.08 pmol/μL of complementary 
(BC1_3232_38AA and BC1_3232_38GG, respectively), mismatch (BC1_3232_38GG and 
BC1_3232_38AA, respectively) and non-complementary (BC1_2731C) in vitro transcript targets. Spectrum 
data was registered 15 minutes after the addition of 40 mM MgCl2. 
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In the presence of 0.03 pmol/μL, the discrimination was not possible probably due to sensitivity 
issues, although, at these minimum concentrations one can see differences between 
complementary and non-complementary targets. This behavior is enhanced with the increase in 
target concentration, i.e. 0.06 pmol/μL. At this target concentration, the BC1_3232A probe 
appears to have better sensibility than the BC1_3232G probe to discriminate between 
complementary and mismatch target. However, BC1_3232G probe did not seem to be able to 
discriminate the single base mismatch until saturation is reached at 0.08 pmol/μL, where 
differences of %Dispersion due to differences in target quantification no longer take effect, i.e. 
the Au-nanoprobes’ %Dispersion can vary for different target concentrations up to saturation, 
above which the %Dispersion no longer varies. In these assays, both BC1_3232A and 
BC1_3232G probes were able to discriminate the corresponding single base mismatch directly 
in the RNA target when using 0.08 pmol/µL of transcript. Although the mismatch demonstrates 
an increase %Dispersion when compared to the non-complementary target, a difference of 10% 
between complementary and mismatch is observed for the BC1_3232A probe and 15% for the 
BC1_3232G probe. This mismatch discrimination may be further enhanced by optimizing 
hybridization conditions, in order to reduce the stabilization induced by the mismatch target at 
0.08 pmol/μL.  
It can also be observed the increase %Dispersion caused by increased concentrations of the 
non-complementary target, although this target clearly did not prove to stabilize the probes. This 
slight increase in stabilization can be due to presence of more nucleic acids that are responsible 
for an increase in the entropy of the system resulting in more stabilization
[78]
. 
It has been recently reported the influence of functionalization in capacity of mismatch 
discrimination
[88]
. Although these Au-nanoprobes’ densities are in accordance to the best 
capacity of discrimination (80 oligo/NP), it is worth mentioning that these studies were 
performed with 40-mer DNA targets, while the RNA targets used in the present report are 
around 400 bases long. The BC1_3232A is less functionalized than BC1_3232G (56 oligo/NP 
and 81 oligo/NP, respectively) and have, without optimization, a better discrimination capacity 
between complementary and non-complementary targets. Even though optimization was not 
carried out, due to material and time constraints, it was possible to demonstrate as proof-of-
concept the discrimination of SNP in RNA using the non-cross-linking method. In addition, with 
the increase of complementary target concentration there is an increase in stability of the Au-
nanoprobes system indicating also the potential of quantification of the system for each allele. 
 
3.4. In vivo RNA transcript detection 
 
The plasmids harboring fragments of interest were transformed in E.coli BL21 (DE3) pLysE cells 
in order to induce in vivo transcription by IPTG. The BC1_3232A probe was the first tested with 
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in vivo transcripts, since it presented the best capacity of detection when using in vitro RNA. 
Before checking the possibility of single mismatch resolution, the first attempt was to verify the 
capacity of hybridization with the complementary target. Thus, E.coli BL21 harboring the 
plasmid pBC1_3232A_38A was submitted to induction with IPTG. As negative control, a E.coli 
BL21 transformed with pUC19 was used. Additionally, the expression induced with IPTG was 
controlled by an assay without adding IPTG. Total RNA extraction was performed after the 
induction of expression by IPTG. The total RNA integrity was confirmed in agarose gel 
(Appendix E). The ratio Abs260nm/Abs230nm was below 1 indicating contaminations with some 
impurities (e.g. phenol). Nonetheless, the non-cross-linking assay was performed using 0.5 μg 
of total RNA. This value was chosen since it was the upper value used in the RNA detection 
reported by Baptista et al.
[78]
. All total RNA samples provided stabilization of the Au-nanoprobes 
system, indicating that the impurities present within the purified transcript are most likely 
hampering the colorimetric assay. One hypothesis is the presence of proteins that may adsorb 
to AuNPs and hamper aggregation upon salt addition, as discussed previously
[115,116,117]
. Hence, 
future optimization of the total RNA extraction is needed in order to achieve samples suitable to 
conduct the non-cross-linking assays with in vivo transcripts. 
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4. CONCLUSIONS AND FUTURE PERSPECTIVES 
The present work was developed with the purpose of verifying if the non-cross-linking method 
would allow to detect single base mismatches in RNA molecules. Therefore DNA biological 
samples gently provided by the IPO, harboring three of SNPs in BRCA1 gene associated with 
breast cancer, were cloned in an expression vector for further in vitro transcription. The 
purification of the transcript revealed to be a limitation in this study, not only because of the low 
yield of the purification step but also due to the sensitivity of the Au-nanoprobes system to 
dielectric changes of the medium. The phenol/chloroform extraction was the only method tested 
for the purification of in vitro transcriptions that revealed to be efficient, allowing to carry out the 
needed non-cross-linking assays. A setback associated with the choice of this method is the 
necessity of quantification of the transcript present in the samples by agarose gel, which is a 
more cumbersome technique when compared to the quantification through UV-visible 
spectroscopy. 
The Au-nanoprobes designed for detection of the RNA fragments were characterized in terms 
of stability, capacity of hybridization and their detection limit. Mostly all Au-nanoprobes showed 
a limit of detection of 0.03 pmol/μL, with maximum discrimination between complementary and 
non-complementary targets attained at 0.12 pmol/μL of synthetic ssDNA. Moreover, the 
synthesized Au-nanoprobes presented a linear variation of their %Dispersion for 
complementary targets up to 0.12 pmol/µL, which allows for target quantification. 
In order to mimic the complexity of real biological samples, a spike-in assay using total RNA 
from S. cerevisiae was performed. The detection of a complementary target was possible up to 
a ratio of 0.25% target/total RNA, which resembles the percentages of RNA expression found in 
real biological samples. The detection of SNP within in vitro transcripts was possible for the 
BC1_3232A and BC1_3232G probes when using 0.08 pmol/μL of RNA. For the other Au-
nanoprobes, the detection of their respective SNPs was inconclusive and may require further 
optimization. For this reason, it is important to perform more assays in order to determine the 
universal capabilities of the non-cross-linking system for SNP detection in RNA. Optimization 
may be achieved through a more homogenous functionalization of the Au-nanoprobes to a level 
where single base mismatch resolution is optimized. Moreover, hybridization conditions and 
comprehensive studies about the kinetics of aggregation could allow to optimize SNP 
discrimination by the non-cross-linking method. Once the mismatch discrimination has been 
optimized, the capacity of allele quantification should be possible by performing the non-cross-
linking assay with differential concentrations of complementary and mismatch targets. In a near 
future optimization of the in vivo transcripts detection can also be performed specially using the 
Au-nanoprobes that thus far allowed to discriminate SNP within in vitro transcripts, i.e. 
BC1_3232A and BC1_3232G probes.   
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APPENDICES 
 
Appendix A - Products of PCR amplification obtained by different set of primers 
 
Table A.1 - Products of PCR amplification obtained by different set of primers. 
Size of the amplicon (pb) 
Plasmid Primers Fw and Rev 
specific to the insert  
Primers pJET1.2 
Fw and Rev 
specific to the 
insert  
Primers pJET 1 and 
primer Rev of the 
insert  
pBC1_2731C 
pBC1_2731T 
381 444 473 
pBC1_3232_38AA 
pBC1_3232_38GG 
394 457 486 
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Appendix B - pJET1.2/blunt vector map. 
 
 
 
 
 
Figure A.1. pJET1.2/blunt vector map. 
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Appendix C - Sequences of the plasmids  
plasmid pBC1_2731C 
    1 GCCCCTGCAG CCGAATTATA TTATTTTTGC CAAATAATTT TTAACAAAAG 
   51 CTCTGAAGTC TTCTTCATTT AAATTCTTAG ATGATACTTC ATCTGGAAAA 
  101 TTGTCCCAAT TAGTAGCATC ACGCTGTGAG TAAGTTCTAA ACCATTTTTT 
  151 TATTGTTGTA TTATCTCTAA TCTTACTACT CGATGAGTTT TCGGTATTAT 
  201 CTCTATTTTT AACTTGGAGC AGGTTCCATT CATTGTTTTT TTCATCATAG 
  251 TGAATAAAAT CAACTGCTTT AACACTTGTG CCTGAACACC ATATCCATCC 
  301 GGCGTAATAC GACTCACTAT AGGGAGAGCG GCCGCCAGAT CTTCCGGATG 
  351 GCTCGAGTTT TTCAGCAAGA TTGGTACTGA TTATGGCACT CAGGAAAGTA 
  401 TCTCGTTACT GGAAGTTAGC ACTCTAGGGA AGGCAAAAAC AGAACCAAAT 
  451 AAATGTGTGA GTCAGTGTGC AGCATTTGAA AACCCCAAGG GACTAATTCA 
  501 TGGTTGTTCC AAAGATAATA GAAATGACAC AGAAGGCTTT AAGTATCCAT 
  551 TGGGACATGA AGTTAACCAC AGTCGGGAAA CAAGCATAGA AATGGAAGAA 
  601 AGTGAACTTG ATGCTCAGTA TTTGCAGAAT ACATTCAAGG TTTCAAAGCG 
  651 CCAGTCATTT GCTCCGTTTT CAAATCCAGG AAATGCAGAA GAGGAATGTG 
  701 CAACATTCTC TGCCCACTCT GGGTCCTTAA AGAAACAAAG TCCAAAAGTC 
  751 ACATCTTTCT AGAAGATCTC CTACAATATT CTCAGCTGCC ATGGAAAATC 
  801 GATGTTCTTC TTTTATTCTC TCAAGATTTT CAGGCTGTAT ATTAAAACTT 
  851 ATATTAAGAA CTATGCTAAC CACCTCATCA GGAACCGTTG TAGGTGGCGT 
  901 GGGTTTTCTT GGCAATCGAC TCTCATGAAA ACTACGAGCT AAATATTCAA 
  951 TATGTTCCTC TTGACCAACT TTATTCTGCA TTTTTTTTGA ACGAGGTTTA 
 1001 GAGCAAGCTT CAGGAAACTG AGACAGGAAT TTTATTAAAA ATTTAAATTT 
 1051 TGAAGAAAGT TCAGGGTTAA TAGCATCCAT TTTTTGCTTT GCAAGTTCCT 
 1101 CAGCATTCTT AACAAAAGAC GTCTCTTTTG ACATGTTTAA AGTTTAAACC 
 1151 TCCTGTGTGA AATTGTTATC CGCTCACAAT TCCACACATT ATACGAGCCG 
 1201 GAAGCATAAA GTGTAAAGCC TGGGGTGCCT AATGAGTGAG CTAACTCACA 
 1251 TTAATTGCGT TGCGCTCACT GCCAATTGCT TTCCAGTCGG GAAACCTGTC 
 1301 GTGCCAGCTG CATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC 
 1351 GTATTGGGCG CTCTTCCGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC 
 1401 GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT 
 1451 ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC 
 1501 AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT 
 1551 AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG 
 1601 GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA 
 1651 GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG 
 1701 TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA GCTCACGCTG 
 1751 TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC 
 1801 ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT 
 1851 CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC 
 1901 TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT 
 1951 TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGGTATC 
 2001 TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG 
 2051 ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC 
 2101 AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT 
 2151 TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT 
 2201 GGTCATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA 
 2251 AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC TTGGTCTGAC 
 2301 AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT 
 2351 TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC 
 2401 GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA 
 2451 CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC 
 2501 CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC CAGTCTATTA 
 2551 ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC 
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 2601 AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG 
 2651 TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT 
 2701 CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT 
 2751 GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT 
 2801 GCATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG 
 2851 GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG GCGACCGAGT 
 2901 TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC 
 2951 TTTAAAAGTG CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA 
 3001 GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC 
 3051 AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA 
 3101 AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT 
 3151 GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG CATTTATCAG 
 3201 GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA 
 3251 ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGCCA CCTGACGTCT 
 3301 AAGAAACCAT TATTATCATG ACATTAACCT ATAAAAATAG GCGTATCACG 
 
 
plasmid pBC1_2731T 
    1 GCCCCTGCAG CCGAATTATA TTATTTTTGC CAAATAATTT TTAACAAAAG 
   51 CTCTGAAGTC TTCTTCATTT AAATTCTTAG ATGATACTTC ATCTGGAAAA 
  101 TTGTCCCAAT TAGTAGCATC ACGCTGTGAG TAAGTTCTAA ACCATTTTTT 
  151 TATTGTTGTA TTATCTCTAA TCTTACTACT CGATGAGTTT TCGGTATTAT 
  201 CTCTATTTTT AACTTGGAGC AGGTTCCATT CATTGTTTTT TTCATCATAG 
  251 TGAATAAAAT CAACTGCTTT AACACTTGTG CCTGAACACC ATATCCATCC 
  301 GGCGTAATAC GACTCACTAT AGGGAGAGCG GCCGCCAGAT CTTCCGGATG 
  351 GCTCGAGTTT TTCAGCAAGA TTGGTACTGA TTATGGCACT CAGGAAAGTA 
  401 TCTCGTTACT GGAAGTTAGC ACTCTAGGGA AGGCAAAAAC AGAACCAAAT 
  451 AAATGTGTGA GTCAGTGTGC AGCATTTGAA AACCCCAAGG GACTAATTCA 
  501 TGGTTGTTCC AAAGATAATA GAAATGACAC AGAAGGCTTT AAGTATCCAT 
  551 TGGGACATGA AGTTAACCAC AGTCGGGAAA CAAGCATAGA AATGGAAGAA 
  601 AGTGAACTTG ATGCTCAGTA TTTGCAGAAT ACATTCAAGG TTTCAAAGCG 
  651 CCAGTCATTT GCTCTGTTTT CAAATCCAGG AAATGCAGAA GAGGAATGTG 
  701 CAACATTCTC TGCCCACTCT GGGTCCTTAA AGAAACAAAG TCCAAAAGTC 
  751 ACATCTTTCT AGAAGATCTC CTACAATATT CTCAGCTGCC ATGGAAAATC 
  801 GATGTTCTTC TTTTATTCTC TCAAGATTTT CAGGCTGTAT ATTAAAACTT 
  851 ATATTAAGAA CTATGCTAAC CACCTCATCA GGAACCGTTG TAGGTGGCGT 
  901 GGGTTTTCTT GGCAATCGAC TCTCATGAAA ACTACGAGCT AAATATTCAA 
  951 TATGTTCCTC TTGACCAACT TTATTCTGCA TTTTTTTTGA ACGAGGTTTA 
 1001 GAGCAAGCTT CAGGAAACTG AGACAGGAAT TTTATTAAAA ATTTAAATTT 
 1051 TGAAGAAAGT TCAGGGTTAA TAGCATCCAT TTTTTGCTTT GCAAGTTCCT 
 1101 CAGCATTCTT AACAAAAGAC GTCTCTTTTG ACATGTTTAA AGTTTAAACC 
 1151 TCCTGTGTGA AATTGTTATC CGCTCACAAT TCCACACATT ATACGAGCCG 
 1201 GAAGCATAAA GTGTAAAGCC TGGGGTGCCT AATGAGTGAG CTAACTCACA 
 1251 TTAATTGCGT TGCGCTCACT GCCAATTGCT TTCCAGTCGG GAAACCTGTC 
 1301 GTGCCAGCTG CATTAATGAA TCGGCCAACG CGCGGGGAGA GGCGGTTTGC 
 1351 GTATTGGGCG CTCTTCCGCT TCCTCGCTCA CTGACTCGCT GCGCTCGGTC 
 1401 GTTCGGCTGC GGCGAGCGGT ATCAGCTCAC TCAAAGGCGG TAATACGGTT 
 1451 ATCCACAGAA TCAGGGGATA ACGCAGGAAA GAACATGTGA GCAAAAGGCC 
 1501 AGCAAAAGGC CAGGAACCGT AAAAAGGCCG CGTTGCTGGC GTTTTTCCAT 
 1551 AGGCTCCGCC CCCCTGACGA GCATCACAAA AATCGACGCT CAAGTCAGAG 
 1601 GTGGCGAAAC CCGACAGGAC TATAAAGATA CCAGGCGTTT CCCCCTGGAA 
 1651 GCTCCCTCGT GCGCTCTCCT GTTCCGACCC TGCCGCTTAC CGGATACCTG 
 1701 TCCGCCTTTC TCCCTTCGGG AAGCGTGGCG CTTTCTCATA GCTCACGCTG 
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 1751 TAGGTATCTC AGTTCGGTGT AGGTCGTTCG CTCCAAGCTG GGCTGTGTGC 
 1801 ACGAACCCCC CGTTCAGCCC GACCGCTGCG CCTTATCCGG TAACTATCGT 
 1851 CTTGAGTCCA ACCCGGTAAG ACACGACTTA TCGCCACTGG CAGCAGCCAC 
 1901 TGGTAACAGG ATTAGCAGAG CGAGGTATGT AGGCGGTGCT ACAGAGTTCT 
 1951 TGAAGTGGTG GCCTAACTAC GGCTACACTA GAAGGACAGT ATTTGGTATC 
 2001 TGCGCTCTGC TGAAGCCAGT TACCTTCGGA AAAAGAGTTG GTAGCTCTTG 
 2051 ATCCGGCAAA CAAACCACCG CTGGTAGCGG TGGTTTTTTT GTTTGCAAGC 
 2101 AGCAGATTAC GCGCAGAAAA AAAGGATCTC AAGAAGATCC TTTGATCTTT 
 2151 TCTACGGGGT CTGACGCTCA GTGGAACGAA AACTCACGTT AAGGGATTTT 
 2201 GGTCATGAGA TTATCAAAAA GGATCTTCAC CTAGATCCTT TTAAATTAAA 
 2251 AATGAAGTTT TAAATCAATC TAAAGTATAT ATGAGTAAAC TTGGTCTGAC 
 2301 AGTTACCAAT GCTTAATCAG TGAGGCACCT ATCTCAGCGA TCTGTCTATT 
 2351 TCGTTCATCC ATAGTTGCCT GACTCCCCGT CGTGTAGATA ACTACGATAC 
 2401 GGGAGGGCTT ACCATCTGGC CCCAGTGCTG CAATGATACC GCGAGACCCA 
 2451 CGCTCACCGG CTCCAGATTT ATCAGCAATA AACCAGCCAG CCGGAAGGGC 
 2501 CGAGCGCAGA AGTGGTCCTG CAACTTTATC CGCCTCCATC CAGTCTATTA 
 2551 ATTGTTGCCG GGAAGCTAGA GTAAGTAGTT CGCCAGTTAA TAGTTTGCGC 
 2601 AACGTTGTTG CCATTGCTAC AGGCATCGTG GTGTCACGCT CGTCGTTTGG 
 2651 TATGGCTTCA TTCAGCTCCG GTTCCCAACG ATCAAGGCGA GTTACATGAT 
 2701 CCCCCATGTT GTGCAAAAAA GCGGTTAGCT CCTTCGGTCC TCCGATCGTT 
 2751 GTCAGAAGTA AGTTGGCCGC AGTGTTATCA CTCATGGTTA TGGCAGCACT 
 2801 GCATAATTCT CTTACTGTCA TGCCATCCGT AAGATGCTTT TCTGTGACTG 
 2851 GTGAGTACTC AACCAAGTCA TTCTGAGAAT AGTGTATGCG GCGACCGAGT 
 2901 TGCTCTTGCC CGGCGTCAAT ACGGGATAAT ACCGCGCCAC ATAGCAGAAC 
 2951 TTTAAAAGTG CTCATCATTG GAAAACGTTC TTCGGGGCGA AAACTCTCAA 
 3001 GGATCTTACC GCTGTTGAGA TCCAGTTCGA TGTAACCCAC TCGTGCACCC 
 3051 AACTGATCTT CAGCATCTTT TACTTTCACC AGCGTTTCTG GGTGAGCAAA 
 3101 AACAGGAAGG CAAAATGCCG CAAAAAAGGG AATAAGGGCG ACACGGAAAT 
 3151 GTTGAATACT CATACTCTTC CTTTTTCAAT ATTATTGAAG CATTTATCAG 
 3201 GGTTATTGTC TCATGAGCGG ATACATATTT GAATGTATTT AGAAAAATAA 
 3251 ACAAATAGGG GTTCCGCGCA CATTTCCCCG AAAAGTGCCA CCTGACGTCT 
 3301 AAGAAACCAT TATTATCATG ACATTAACCT ATAAAAATAG GCGTATCACG 
 
 
plasmid pBC1_3232_38AA 
 
    1 GCCCCTGCAG CCGAATTATA TTATTTTTGC CAAATAATTT TTAACAAAAG 
   51 CTCTGAAGTC TTCTTCATTT AAATTCTTAG ATGATACTTC ATCTGGAAAA 
  101 TTGTCCCAAT TAGTAGCATC ACGCTGTGAG TAAGTTCTAA ACCATTTTTT 
  151 TATTGTTGTA TTATCTCTAA TCTTACTACT CGATGAGTTT TCGGTATTAT 
  201 CTCTATTTTT AACTTGGAGC AGGTTCCATT CATTGTTTTT TTCATCATAG 
  251 TGAATAAAAT CAACTGCTTT AACACTTGTG CCTGAACACC ATATCCATCC 
  301 GGCGTAATAC GACTCACTAT AGGGAGAGCG GCCGCCAGAT CTTCCGGATG 
  351 GCTCGAGTTT TTCAGCAAGA TGGCAACGAA ACTGGACTCA TTACTCCAAA 
  401 TAAACATGGA CTTTTACAAA ACCCATATCG TATACCACCA CTTTTTCCCA 
  451 TCAAGTCATT TGTTAAAACT AAATGTAAGA AAAATCTGCT AGAGGAAAAC 
  501 TTTGAGGAAC ATTCAATGTC ACCTGAAAGA GAAATGGGAA ATGAGAACAT 
  551 TCCAAGTACA GTGAGCACAA TTAGCCGTAA TAACATTAGA GAAAATGTTT 
  601 TTAAAGAAGC CAACTCAAGC AATATTAATG AAGTAGGTTC CAGTACTAAT 
  651 GAAGTGGGCT CCAGTATTAA TGAAATAGGT TCCAGTGATG AAAACATTCA 
  701 AGCAGAACTA GGTAGAAACA GAGGGCCAAA ATTGAATGCT ATGCTTAGAT 
  751 TAGGGGTTTT GCAACATCTT TCTAGAAGAT CTCCTACAAT ATTCTCAGCT 
  801 GCCATGGAAA ATCGATGTTC TTCTTTTATT CTCTCAAGAT TTTCAGGCTG 
  851 TATATTAAAA CTTATATTAA GAACTATGCT AACCACCTCA TCAGGAACCG 
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  901 TTGTAGGTGG CGTGGGTTTT CTTGGCAATC GACTCTCATG AAAACTACGA 
  951 GCTAAATATT CAATATGTTC CTCTTGACCA ACTTTATTCT GCATTTTTTT 
 1001 TGAACGAGGT TTAGAGCAAG CTTCAGGAAA CTGAGACAGG AATTTTATTA 
 1051 AAAATTTAAA TTTTGAAGAA AGTTCAGGGT TAATAGCATC CATTTTTTGC 
 1101 TTTGCAAGTT CCTCAGCATT CTTAACAAAA GACGTCTCTT TTGACATGTT 
 1151 TAAAGTTTAA ACCTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC 
 1201 ATTATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT 
 1251 GAGCTAACTC ACATTAATTG CGTTGCGCTC ACTGCCAATT GCTTTCCAGT 
 1301 CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG 
 1351 AGAGGCGGTT TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC 
 1401 GCTGCGCTCG GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG 
 1451 CGGTAATACG GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG 
 1501 TGAGCAAAAG GCCAGCAAAA GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT 
 1551 GGCGTTTTTC CATAGGCTCC GCCCCCCTGA CGAGCATCAC AAAAATCGAC 
 1601 GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG 
 1651 TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT 
 1701 TACCGGATAC CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC 
 1751 ATAGCTCACG CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG 
 1801 CTGGGCTGTG TGCACGAACC CCCCGTTCAG CCCGACCGCT GCGCCTTATC 
 1851 CGGTAACTAT CGTCTTGAGT CCAACCCGGT AAGACACGAC TTATCGCCAC 
 1901 TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA TGTAGGCGGT 
 1951 GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGGAC 
 2001 AGTATTTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG 
 2051 TTGGTAGCTC TTGATCCGGC AAACAAACCA CCGCTGGTAG CGGTGGTTTT 
 2101 TTTGTTTGCA AGCAGCAGAT TACGCGCAGA AAAAAAGGAT CTCAAGAAGA 
 2151 TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC GAAAACTCAC 
 2201 GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT CACCTAGATC 
 2251 CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA 
 2301 AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG 
 2351 CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCTGACTCCC CGTCGTGTAG 
 2401 ATAACTACGA TACGGGAGGG CTTACCATCT GGCCCCAGTG CTGCAATGAT 
 2451 ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA ATAAACCAGC 
 2501 CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCTCC 
 2551 ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT 
 2601 TAATAGTTTG CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC 
 2651 GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA ACGATCAAGG 
 2701 CGAGTTACAT GATCCCCCAT GTTGTGCAAA AAAGCGGTTA GCTCCTTCGG 
 2751 TCCTCCGATC GTTGTCAGAA GTAAGTTGGC CGCAGTGTTA TCACTCATGG 
 2801 TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC CGTAAGATGC 
 2851 TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT 
 2901 GCGGCGACCG AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC 
 2951 CACATAGCAG AACTTTAAAA GTGCTCATCA TTGGAAAACG TTCTTCGGGG 
 3001 CGAAAACTCT CAAGGATCTT ACCGCTGTTG AGATCCAGTT CGATGTAACC 
 3051 CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC ACCAGCGTTT 
 3101 CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA GGGAATAAGG 
 3151 GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG 
 3201 AAGCATTTAT CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA 
 3251 TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG 
 3301 CCACCTGACG TCTAAGAAAC CATTATTATC ATGACATTAA CCTATAAAAA 
 
plasmid pBC1_3232_38GG 
    1 GCCCCTGCAG CCGAATTATA TTATTTTTGC CAAATAATTT TTAACAAAAG 
   51 CTCTGAAGTC TTCTTCATTT AAATTCTTAG ATGATACTTC ATCTGGAAAA 
  101 TTGTCCCAAT TAGTAGCATC ACGCTGTGAG TAAGTTCTAA ACCATTTTTT 
63 
 
  151 TATTGTTGTA TTATCTCTAA TCTTACTACT CGATGAGTTT TCGGTATTAT 
  201 CTCTATTTTT AACTTGGAGC AGGTTCCATT CATTGTTTTT TTCATCATAG 
  251 TGAATAAAAT CAACTGCTTT AACACTTGTG CCTGAACACC ATATCCATCC 
  301 GGCGTAATAC GACTCACTAT AGGGAGAGCG GCCGCCAGAT CTTCCGGATG 
  351 GCTCGAGTTT TTCAGCAAGA TGGCAACGAA ACTGGACTCA TTACTCCAAA 
  401 TAAACATGGA CTTTTACAAA ACCCATATCG TATACCACCA CTTTTTCCCA 
  451 TCAAGTCATT TGTTAAAACT AAATGTAAGA AAAATCTGCT AGAGGAAAAC 
  501 TTTGAGGAAC ATTCAATGTC ACCTGAAAGA GAAATGGGAA ATGAGAACAT 
  551 TCCAAGTACA GTGAGCACAA TTAGCCGTAA TAACATTAGA GAAAATGTTT 
  601 TTAAAGGAGC CAGCTCAAGC AATATTAATG AAGTAGGTTC CAGTACTAAT 
  651 GAAGTGGGCT CCAGTATTAA TGAAATAGGT TCCAGTGATG AAAACATTCA 
  701 AGCAGAACTA GGTAGAAACA GAGGGCCAAA ATTGAATGCT ATGCTTAGAT 
  751 TAGGGGTTTT GCAACATCTT TCTAGAAGAT CTCCTACAAT ATTCTCAGCT 
  801 GCCATGGAAA ATCGATGTTC TTCTTTTATT CTCTCAAGAT TTTCAGGCTG 
  851 TATATTAAAA CTTATATTAA GAACTATGCT AACCACCTCA TCAGGAACCG 
  901 TTGTAGGTGG CGTGGGTTTT CTTGGCAATC GACTCTCATG AAAACTACGA 
  951 GCTAAATATT CAATATGTTC CTCTTGACCA ACTTTATTCT GCATTTTTTT 
 1001 TGAACGAGGT TTAGAGCAAG CTTCAGGAAA CTGAGACAGG AATTTTATTA 
 1051 AAAATTTAAA TTTTGAAGAA AGTTCAGGGT TAATAGCATC CATTTTTTGC 
 1101 TTTGCAAGTT CCTCAGCATT CTTAACAAAA GACGTCTCTT TTGACATGTT 
 1151 TAAAGTTTAA ACCTCCTGTG TGAAATTGTT ATCCGCTCAC AATTCCACAC 
 1201 ATTATACGAG CCGGAAGCAT AAAGTGTAAA GCCTGGGGTG CCTAATGAGT 
 1251 GAGCTAACTC ACATTAATTG CGTTGCGCTC ACTGCCAATT GCTTTCCAGT 
 1301 CGGGAAACCT GTCGTGCCAG CTGCATTAAT GAATCGGCCA ACGCGCGGGG 
 1351 AGAGGCGGTT TGCGTATTGG GCGCTCTTCC GCTTCCTCGC TCACTGACTC 
 1401 GCTGCGCTCG GTCGTTCGGC TGCGGCGAGC GGTATCAGCT CACTCAAAGG 
 1451 CGGTAATACG GTTATCCACA GAATCAGGGG ATAACGCAGG AAAGAACATG 
 1501 TGAGCAAAAG GCCAGCAAAA GGCCAGGAAC CGTAAAAAGG CCGCGTTGCT 
 1551 GGCGTTTTTC CATAGGCTCC GCCCCCCTGA CGAGCATCAC AAAAATCGAC 
 1601 GCTCAAGTCA GAGGTGGCGA AACCCGACAG GACTATAAAG ATACCAGGCG 
 1651 TTTCCCCCTG GAAGCTCCCT CGTGCGCTCT CCTGTTCCGA CCCTGCCGCT 
 1701 TACCGGATAC CTGTCCGCCT TTCTCCCTTC GGGAAGCGTG GCGCTTTCTC 
 1751 ATAGCTCACG CTGTAGGTAT CTCAGTTCGG TGTAGGTCGT TCGCTCCAAG 
 1801 CTGGGCTGTG TGCACGAACC CCCCGTTCAG CCCGACCGCT GCGCCTTATC 
 1851 CGGTAACTAT CGTCTTGAGT CCAACCCGGT AAGACACGAC TTATCGCCAC 
 1901 TGGCAGCAGC CACTGGTAAC AGGATTAGCA GAGCGAGGTA TGTAGGCGGT 
 1951 GCTACAGAGT TCTTGAAGTG GTGGCCTAAC TACGGCTACA CTAGAAGGAC 
 2001 AGTATTTGGT ATCTGCGCTC TGCTGAAGCC AGTTACCTTC GGAAAAAGAG 
 2051 TTGGTAGCTC TTGATCCGGC AAACAAACCA CCGCTGGTAG CGGTGGTTTT 
 2101 TTTGTTTGCA AGCAGCAGAT TACGCGCAGA AAAAAAGGAT CTCAAGAAGA 
 2151 TCCTTTGATC TTTTCTACGG GGTCTGACGC TCAGTGGAAC GAAAACTCAC 
 2201 GTTAAGGGAT TTTGGTCATG AGATTATCAA AAAGGATCTT CACCTAGATC 
 2251 CTTTTAAATT AAAAATGAAG TTTTAAATCA ATCTAAAGTA TATATGAGTA 
 2301 AACTTGGTCT GACAGTTACC AATGCTTAAT CAGTGAGGCA CCTATCTCAG 
 2351 CGATCTGTCT ATTTCGTTCA TCCATAGTTG CCTGACTCCC CGTCGTGTAG 
 2401 ATAACTACGA TACGGGAGGG CTTACCATCT GGCCCCAGTG CTGCAATGAT 
 2451 ACCGCGAGAC CCACGCTCAC CGGCTCCAGA TTTATCAGCA ATAAACCAGC 
 2501 CAGCCGGAAG GGCCGAGCGC AGAAGTGGTC CTGCAACTTT ATCCGCCTCC 
 2551 ATCCAGTCTA TTAATTGTTG CCGGGAAGCT AGAGTAAGTA GTTCGCCAGT 
 2601 TAATAGTTTG CGCAACGTTG TTGCCATTGC TACAGGCATC GTGGTGTCAC 
 2651 GCTCGTCGTT TGGTATGGCT TCATTCAGCT CCGGTTCCCA ACGATCAAGG 
 2701 CGAGTTACAT GATCCCCCAT GTTGTGCAAA AAAGCGGTTA GCTCCTTCGG 
 2751 TCCTCCGATC GTTGTCAGAA GTAAGTTGGC CGCAGTGTTA TCACTCATGG 
 2801 TTATGGCAGC ACTGCATAAT TCTCTTACTG TCATGCCATC CGTAAGATGC 
 2851 TTTTCTGTGA CTGGTGAGTA CTCAACCAAG TCATTCTGAG AATAGTGTAT 
 2901 GCGGCGACCG AGTTGCTCTT GCCCGGCGTC AATACGGGAT AATACCGCGC 
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 2951 CACATAGCAG AACTTTAAAA GTGCTCATCA TTGGAAAACG TTCTTCGGGG 
 3001 CGAAAACTCT CAAGGATCTT ACCGCTGTTG AGATCCAGTT CGATGTAACC 
 3051 CACTCGTGCA CCCAACTGAT CTTCAGCATC TTTTACTTTC ACCAGCGTTT 
 3101 CTGGGTGAGC AAAAACAGGA AGGCAAAATG CCGCAAAAAA GGGAATAAGG 
 3151 GCGACACGGA AATGTTGAAT ACTCATACTC TTCCTTTTTC AATATTATTG 
 3201 AAGCATTTAT CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA 
 3251 TTTAGAAAAA TAAACAAATA GGGGTTCCGC GCACATTTCC CCGAAAAGTG 
 3301 CCACCTGACG TCTAAGAAAC CATTATTATC ATGACATTAA CCTATAAAAA 
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Appendix D - Isolation of in vitro RNA transcripts by agarose gel purification 
 
Figure A.2. Agarose gel electrophoresis of transcripts after purification by freeze and 
squeeze method. Electrophoresis (80 V, 1 h30 ) in agarose gel (2%, 1x TBE, 0.5x Gelred TM). L) 
GeneRuler™ DNA Ladder Mix, ready-to-use 1) BC1_2731C template (473 pb); 2) BC1_2731C in vitro 
transcription (431b); 3) purified BC1_2731C in vitro transcription (431b). 
 
  
L             1           2         3 
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Appendix E - Extraction of total RNA from E.coli BL21 clones 
 
 
Figure A.3. Agarose gel electrophoresis of Total RNA extracted from E.coli BL21 clones.  
Electrophoresis (90 V, 1 hour) in agarose gel (2%, 1x TBE, 0.5x Gelred 
TM
). L) RiboRuler
TM
High Range 
RNA Ladder. 1) pBC1_3232A_38A induced with IPTG, 2) pBC1_3232A_38A without IPTG  induction 3) 
pUC19 induced with IPTG 4) pUC19 without IPTG induction. 
  L       1         2       3        4 
